The Australasian Society of Nephrology  by unknown
Kidney International, Vol. 26 (1984), pp. 228—247
Abstracts
The Australasian Society of Nephrology
Surfers Paradise, Australia
February 29 — March 2, 1984
Macrophages, fibrin, and human renal allograft rejection. W. W.
Hancock, F. R. Rick/es, and R. C. Atkins. Department of Nephrol-
ogy, Prince Henry's Hospital, Melbourne, and Department qfHema-
lology, University of Connecticut, Farmington, Connecticut. Analysis
with monoclonal antibodies has shown that macrophages constitute
one of the main cell types present during acute human renal allograft
rejection, although their precise function(s) remains undetermined.
Macrophages may be activated directly by endotoxin. or indirectly by
lymphokines (for example, MIF) resulting in expression of the pro-
coagulant tissue factor (TF) and activation of the extrinsic pathway of
coagulation. We therefore investigated whether intragraft macro-
phages might express TF and hence initiate local fibrin deposition,
leading to graft ischemia. Twenty-seven renal biopsy specimens were
stained using a 4-layer imrnunoperoxidase technique. lntragraft mac-
rophages were identified using monoclonal antibodies to monocytes,i'-
cells, and other leucocytes. Activation of the extrinsic pathway was as-
sessed by comparing the sites of fibrin deposition with the distribution
of TF niacrophages (HTF-l). Fibrin deposition as a result of intrinsic
pathway activation was assessed using antibodies to Hageman factor,
factor VIII, and albumin. Twenty-four of the 27 renal biopsy speci-
mens displayed both fibrin deposits and prominent macrophage infil-
tration. Of these 24 biopsy specimens, 20 showed varying proportions
to TF macrophages (5 to 90%). The distribution of these TF mac-
rophages was generally correlated with sites of fibrin and fibronectin
deposition. In contrast, only one biopsy specimen contained TF' mac-
rophages without fibrin. However, several biopsy specimens showed
corresponding deposits of Hageman factor. TF macrophages, and fi-
brin, suggesting activation of both pathways of coagulation. 'I'hese
findings show that intragraft macrophages frequently exhibit an anti-
gen (TF) characteristic of lymphokine-induced activation. Indeed,
since Iymphokine-induced activation of macrophages and fibrin depo-
sition are central features of DTH reactions, these results in humans
complement recent rodent data concerning the importance of DTI-I re-
actions in graft rejection. In addition, it appears that fibrin deposition
within rejecting human renal allografts is mainly the result of macroph-
age-related TF activation of the extrinsic pathway of coagulation.
Controlled clinical trial of cyclosporin A (CSA) in cadaveric donor re-
nal transplantation (CDRT). A. G. R. Sheil, B. M. Hall, D. J. Tiller,
M. S. Stephen, J. P. harris, U. U. Duggin, J. S. Ilorvath, J. R. John-
con, I. R. Rogers, and J. Boulas. Department of Surge,y, The Uni-
versity of Sydney and Renal Unit, Royal Prince A/fred Hospital,
Sydney, Australia. Sixty patients (pts) were randomly allocated in a
prospective controlled trial of the use of CSA for the first CDRT com-
pared with azathioprine (Az). prednisone (pred). and antithymocyte
globulin (ATG). CSA was given in the dose 17 mg/kg by mouth (po)
with gradual reduction. Rejection (rjn) was treated in both groups (gps)
by pulse methylprednisolone therapy over 3 days. The trial has ex-
tended for 3 years. Minimum follow-up is 6 months. Of 30 CSA pts 2
(7%) died, One (3%) Az Pt died. Graft survivals in the CSA gp at I and
2 years were 70 and 65%. In the control gp respective survivals were
80% and 69%. The causes of 11(37%) graft failures in the CSA gp were
rjn 8 (27%), death of pt (I), bleeding following biopsy (1), and techni-
cal failure (TF) (I). In the AZ gp 7 (23%) grafts failed because of un
and one was a TF. In the CSA pts good function occurred after opera-
tion in 5 (17%) while persisting non-function requiring change of
therapy occurred in four (13%). The remaining pts achieved good func-
tion in 4 to 38 (mean 23) days while full CSA treatment continued, In
the Az gp 3 grafts were nonfunctional because of rjn or TF. Immedi-
ately good function occurred in 12 (40%). The remaining 15 pts diures-
ed 2 to 23 (mean 13) days post-op. Bone marrow depression was com-
mon in the Az gp hut absent in the CSA gp; viral infections were less
in the CSA gp. Skin cancer occurred in 5 Az pts and I CSA pt. There
is no significant difference in pt or graft survival between the 2 gps.
While CSA is as potent an immune suppressive agent as standard
therapy, significant rejection does occur. To enhance efficacy of CSA
it may prove advantageous to administer CSA intravenously before the
operation and/or add other immuno-suppressants. Whether long-term
complications in the CSA gp will be fewer than is usual with standard
therapy remains to be seen.
Effect of cyclosporin A (CsA) on early function of cadaver renal grafts.
B. M. Ha/I, D. J. Tiller, J. S. Horvath, G. G. Duggin, J. J. Johnson,
and A. U. Shell. Renal Unit, Royal Prince Afred Hospital, Cam-
perdown, New South Wales. The early function of grafts in 50 patients
given CsA and 45 given azathioprine (AZA) were compared. A dose
of 17 mg/kg/day of CsA was given for 4 weeks, then reduced. The kid-
ney donor and preservation parameters were similar in each group. Im-
mediate function occurred in 13 CsA (25%) and 14 (31%) AZA pa-
tients. Eight CsA (16%) and eight AZA (17.8%) patients' kidneys were
lost without functioning, due to hyperacute (5) and acute (7) rejection,
nonrejection (3), and death (I). Of the kidneys which functioned, the
time at which the serum creatinine became < 400 zmoles/liter was sig-
nificantly delayed in CsA, 25.5 (1—98) days, median (range), compared
to the AZA, 11.5 (1—42) days, (P < 0.007). Nine patients whose oI-
iguria did not reverse on CsA had a diffuse interstitial fibrosis never
seen in AZA patients. Factors contributing to oliguria in these patients
were assessed by comparing their donor, preservation, and post-trans-
plant parameters to those of 13 CsA treated patients with immediate
grat't function. Significant differences were donor hypotension requir-
ing vasoconstrictors (9 vs. I) and rejection episodes in the first 3
months, 5 (2—10) vs. 2 (0—4). Even though trough CsA levels were
lower in oliguric patients. 117 159 vs. 155 218 ng/mI, seven of
these patient grafts commenced to function within Ito 10 days of ceas-
ing CsA and achieved minimum serum creatinine of 180 (140—325)
smoles/liter. CsA therapy may delay recovery of acute transplant re-
nal failure and the combination of donor hypotension and rejection may
prevent recovery without cessation of CsA.
Importance of recipient hydration for early renal allograft function. J.
M. Quinn, G. A. Balderson, 1. R. Hardie, P. W. H. Woodruff andf.
J. B. Petrie. Renal Transplant Unit, Princess Alexandra Hospital and
Department of Surgesy, University of Queensland, Brisbane, Aus-
tralia. Plans to introduce cyclosporin, with its nephrotoxicity, co-
incided with reduced immediate graft function (IF) to 33%, and so
raised concern about the adequacy of dialysis facilities. Donor and re-
cipient protocols were reviewed, and chlorpromazine (CPZ) donor pre-
treatment. and good recipient hydration were introduced. Results for
1983 (group A: N = 30) have been compared with those of the previ-
ous 18 months (group B: N = 82). Donors in both groups had similar
age, cause of death, renal function, vasoconstrictor therapy, warm is-
chemia and storage times (total ischemia A: 21.3 3.6 hr; B: 21.9
3.4 hr). Significantly more donors in group A had CPZ pretreatment
(73% vs. 40%; X2 = 8.34, P < 0.004). The two recipient groups were
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similar in terms of age, sex, and graft number; fewer in group A had
been on hemodialysis (73% vs. 92%; X2 = 5.59, P = 0.018); 24-hr pen-
operative fluid volume was significantly greater in group A (5.29 2.19
liter vs. 4.04 1.0 liter; Z = 3.572, P = 0.0004). Group A had sig-
nificantly better IF (63% vs. 33%; X2 = 7.181, P = 0.007). Discrimi-
nant analysiS showed perioperative fidid volume to be the most signifi-
cant factor in immediate graft function, with CPZ pretreatment and re-
cipient age also exerting some influence. Three-month graft survival
was similar in both groups, whether there was immediate function (IF)
or delayed function (DF) (A:IF = 90%; DF = 91%; B:81%; DF =
80%). Clearly, adequate recipient hydration in the perioperative pe-
riod contributes significantly to early graft function.
Bone disease (BD) after renal transplantation (Tx). R. G. Fassett, N.
Fazzelari, J. McClure, and D. J. Pugsley. Renal Unit, The Queen Eliz-
abeth,Hospital, Woodville, South Australia. To determine the effect of
Tx on BD, 20 subjects (14 male, 6 female, mean age 41.2 years) had
bone biopsies (BBx) and biochemistry (Ca, P04, ALP, PTH) per-
formed before and 12 months after Tx. Undecalcified BBx sections
were stained using the Van Kossa technique with hemotoxylin and
eosin. Significant changes occurred in bone histomorphometric and
biochemical parameters shown in the table:
Pre-transpiant Post-transplant P
Total bone volume 26.1 8.9 21.0 4.7 <0.006
Osteoid volume 1.3 1.3 0.6 0.4 <0.009
Osteoid surface extent 67.6 23.9 44.5 19.9 <0.0007
Serum parathyroid
hormone 20.9 7.0 9.6 3.7 <0.0005
Serum phosphate 1.86 0.78 1.15 0.53 <0.005
Although not statistically significant there was a decrease in resorption
indices, calcification fronts, and ALP after Tx — serum calcium levels
were unchanged overall; however, five of 20 subjects became hyper-
calcemic — ten of 20 subjects became hypophosphateniic. By 12
months after Tx secondary hyperparathyroidism had improved al-
though PTH levels did not return to normal even in those with good
Tx function. Of seven subjects with osteomalacia three improved but
four had persistent osteomalacia and four subjects developed os-
teomalacia after Tx. This occurred despite good Tx function and may
have been related to hypophosphatemia.
Prognosis for recipients surviving 10 years after cadaveric renal trans-
plantation. J. F. Mahony, E. Savdie, R. J. Caterson, T. Furlong, J. H.
Stewart, and A. G. R. Shell. Department of Medical Research, Sydney
Hospital and Renal Unit, Royal North Shore Hospital, St. Leonards,
New South Wales. Of the 93 recipients (M:F 40:53, aged 35.1 10.3
at operation) of first cadaveric renal allografts (Tx) between Septem-
ber 1967 and September 1973 who survived at least 10 years, 88 were
survivors from the first 218 such patients at Sydney Hospital and five
patientstreated there initially had the operation done elsewhere. Sev-
enty-five patients still had functioning first Tx, 12 second and two third
Tx at 10 years, while four required dialysis; 35 had had skin cancer and
7 neoplasia elsewhere. Actuarial patient survival for the group was
71.8% at 15 years. Causes of death were ischemic heart disease (7),
neoplasm (3 — colon, breast, and melanoma), uremia (2), infection,
and gastrointestinal hemorrhage (I each). In the group of 75 with a
functioning first TX at 10 years, mean serum creatinine levels were
similar at I and 5 years but significantly higher at 10 years post-trans-
plant (129.2, 116.7 and 144.1 imoles/liter respectively, P < 0.01). For
the ten patients with functioning first Tx at 15 years, mean serum cre-
atinine levels had risen from 101.0 at ten years to 178.0 i.moles/liter (P
< 0.02) five years later. Actuarial graft survival for functioning Tx at
ten years was 70.5% at 15 years. Nine patients died with functioning
Tx but the remaining eight Tx lost after ten years failed because of
chronic rejection. Five-year survival prospects remained encouraging
in patients alive ten years after cadaveric renal transplantation. 1-low-
ever, these Tx began to lose function between five and ten years and
chronic rejection was the major cause of later Tx failure. The major
cause of death after ten years was ischemic heart disease, followed by
cancer.
Radiological signs and bone histology in patients on maintenance dial-
ysis. Y. L. Chan, T. Furlong, J. F. Mahony, W. K. Wang, E. Savdie,
R. J. Caterson, and S. Posen. Renal and Endocrine Units, Royal
North Shore Hospital, St. Leonards, New South Wales. Conventional
roentgenograms were taken of both hands, lumbosacral spine, pelvis,
and skull in 78 patients (35 males and 43 females, aged 17 to 69 years)
who had been maintained on dialysis for 1 month to 11 years and who
consented to an iliac crest biopsy. The histological findings were hyper-
parathyroidism (HPT) in 18 patients, pure osteomalacia (OM) in 26,
and mixed lesions in 50. Subperiosteal erosions of the phalanges were
present in 20 (34%) of 59 patients with, and none of 19 patients with-
out histological HPT. Of 18 patients with skeletal cysts, 12 also had
subperiosteal erosions, 3 only histological HPT and 3 histological OM.
Patients with erosions or cystic lesions had more severe HPT than
those without, but the combination of the two radiological lesions was
of no predictive value. In 40 patients (5 1%) with radiological rugger-jersey" spine, histological HPT was more severe than in those with-
out it. Nevertheless, 8 of the 40 had no histological HPT. Generalized
osteosclerosis, present in 8 patients, was associated with a higher mean
total trabecular bone area, fractional mineralized bone area and frac-
tional osteoid area. Generalized osteopenia was present in ten pa-
tients. Apart from a lower mean total trabecular bone area and frac-
tional mineralized bone area, there were no histological differences be-
tween osteopenic and non-osteopenic patients. Although 42 patients(52%) with vascular calcification had a higher mean serum creatinine
(2.60 0.23 vs. 2.49 0.26 mmoles/liter, P < 0.05) than patients with-
out, mean serum Pi and Ca-Pi product were not different in the two
groups. Vascular calcification was not correlated with any histologic
parameter.
Hepatitis B vaccination. D. C. H. Harris, E. B. Crewe, andf. H. Stew-
art. Westmead Centre, Wesrmead, New South Wales. When hepatitis
B was detected in one patient in a hospital hemodialysis center, pas-
sive and active immunization of staff and patients was commenced. Six
staff members and 19 patients received passive immunization with 4 ml
of hyperimmune globulin (CSL). Commencing 1 week later, hepatitis
B vaccine (H-B-VAX, MSD) was given at 0, 1, and 6 months to 30 pa-
tients (2 ml) and 13 staff members (I ml). HB Ag and anti-HB (RIA-
sandwich binding) and anti-HB (competitive binding) were monitored
monthly. Anti-HB levels are expressed as counts/ml above baseline
(mean of negative controls + 3 sD). All those vaccinated remained
HBAg negative, and four patiehts have been anti-HB positive and
(cAb negative), two persistently. Seventeen (ex 19) patients have re-
ceived a full course of passive and active immunization. Two males
have had no immune response, and the mean anti-HB, level at 5
months was 3,515 (SD 5,661), and (at 7 months) 10,117 (SD 11,712). Fe-
males (11,580 at 7 months) had a brisker response than males (8,400).
Sex (ex 11) patients have completed the course of active (without pas-
sive) immunization, and only two (ex6) have had an antibody re-
sponse; a further two who have not completed the course have re-
sponded. All six staff members who received passive and active im-
munization have had a vigorous anti-HB, response at 5 months (mean
18,397, su 9,005) and 7 months (mean 27,714 SD 5,181). Six of seven
staff members who received active immunization alone have re-
sponded briskly at 5 months (mean 12,525, SD 8,505) and 7 months
(mean 21,212, SD 11,341). Four staff members were anti-HR positive
ab inition (mean 17,661, SD 14,225) and were not vaccinated. Staff re-
sponded more briskly than patiehts, and the response was more vig-
orous in patients (and possibly staff) who received both active and pas-
sive immunization.
Custom hemodialysis (CHD) with bicarbonate (HCO3) dialysates. M.
Roberts, M. Blumenkrantz, L. Francisco, B. Otten, S. Salihmogh-
edda, R. Boken, M. Spira, andJ. Meihaus. Organon Teknika, St. Vin-
cent & GarfieldMedical Centers, Los Angeles, California. Renal fail-
ure patients, either post-operative and/or with multiple organ system
failure, often present metabolic and hemodynamic abnormalities dif-
fering significantly from stable maintenance hemodialysis (HD) pa-
tients. They frequently have a unique combination of electrolyte acid-
base disorders which can be treated by CHD. Individualized dialys-
ates are readily prepared with the REDY sorbent system because of
its small dialysate volume (6 liters). The purpose of this study was to
devise a minimum number of basic HCO3 dialysates and investigate
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various factors necessary to normalize the patient's pH and electro-
lyte status. Serum electrolytes and arterial blood gases were measured
pre- and post-HD. Approximately 170 dialyses were performed with
CHD in 70 patients in 12 months. Many of these patients were in in-
tensive care units and received TPN. Data were collected on 55 dialy-
ses in 26 patients. During the course of the study the three basic di-
alysates were modified periodically to more appropriately correct the
patient's electrolyte and acid-base balance. Hyponatremia and mixed
acid-base disorders, especially the combination of metabolic acidosis
with respiratory alkalosis, were common. Five basic HCO3 dialysates
were devised, varying from 0 to 100 rnEq/liter. The amount of urea re-
moved and the amount of potassium acetate added to the dialysate af-
fected selection of the appropriate dialysate since both of these pro-
vided HCO3. For the correction of hyponatremia, concentrated NaCI
was added to increase the dialysate Na to 155/mEq/liter HCO3 dialy-
sate, along with a high Na and dextrose concentration (800 mg/dl),
combined with liberal amounts of 25% albumin solution minimized the
incidence of removal by ultrafiltration (5 to 8% of body weight). CHD
with the appropriate HCO3-dialysate, individualized for the patient,
predictably normalized the pH, and corrected serum electrolyte con-
centration in greater than 90% of the unstable renal failure patients.
Continuous ambulatory peritoneal dialysis (CAPD): 5 years experi-
ence. R. J. Rigby, J. J. B. Petrie, and J. L. Butler. Renal Unit, Prin-
cess Alexandra Hospital, Brisbane, Australia. Seventy-one patients
were trained for 75 periods of CAPD. Ages ranged from 7 to 66 years
= 42 151 and 66% were female. Analgesic nephropathy was the
cause of renal failure in 29% and diabetes in 4%. The duration of CAPD
treatment ranged from I to 60 months, mean 12 months, median 8
months. Twenty-nine patients are currently on CAPD for a median of
12.8 months. The actuarial survival of the technique (counting trans-
plants as lost to follow-up and deaths on CAPD as failures) was 72%
at I year and 48% at 2 years. Five patients died on or within 3 months
of CAPD treatment giving actuarial survival of 93% at 1 year and 80%
at 2 years. There were six other deaths. Twenty-five transplants were
performed and seventeen are still functioning. The 1 year risk of peri-
tonitis was 73% for first episodes and 47% for second episodes. Sev-
enty-eight percent of the total infections occurred in 56% of the pa-
tients. The actuarial survival of first peritoneal catheters was 74% at 1
year and 56% at 2 years. For second catheters survival was 45% at I
year. Eighteen patients on CAPD for greater than 1 year did not re-
ceive routine folate, iron, calcium, or vitamin D supplements. Low se-
rum and RBC folate developed in four, but only one showed an in-
crease in MCV. Serum ferritin fell to less than 20 zg/1iter in six pa-
tients. PTH levels decreased in one and increased in seven, but
changes in alkaline phosphatase and progressive radiological ab-
normalities were uncommon.
Results in a CAPD training program. J. Moran, C. Wright, M.
O'Malley, I. Vellar, and J. Niall. St. Vincent's Hospital, Melbourne,
Australia. The results in a CAPD program which has entered 69 pa-
tients since February, 1978, are presented. All patients with ESRD
were offered CAPD as first choice of therapy. Eighteen patients were
entered as permanent CAPD candidates and 51 were entered while
awaiting renal transplantation (holding" group). Only four patients
(two in each group) could not be established on the technique. The rate
of subsequent patient dropout was high, with 24 such "technique fail-
ures." The major cause of failure was fungal peritonitis (10 patients,
42% of failures) followed by patient preference for HD (5 patients,
21%), 3 non-CAPD-related deaths (two sudden cardiovascular, one
treatment withdrawal, 12.5%), two CAPD-related deaths (both recur-
rent bowel obstruction, 8%) and one bowel obstruction. Of the in-
tended permanent group, 11 are continuing CAPD, six have died (three
while still on CAPD) and one is alive on HD. Renal transplantation was
successfully performed on 16 patients from the "holding" group. There
were 133 episodes of peritonitis in 1033 patient months, a rate of one
per 7.8 patient months of treatment. Only one death was related to
peritonitis (C. albicans). Life table analyses of results will be pre-
sented. CAPD is a successful form of long-term therapy for patients
who are unsuitable for transplantation. These patients have better re-
sults than patients who know CAPD to be a temporary holding pro-
cedure.
Two years of CAPD for all patients entering a transplantation pro-
gram. D. J. Tiller, J. S. Horvath, J. Johnson, B. Hall, and G. Duggin.
Royal Prince Alfred Hospital, Missenden Road, Camperdown, New
South Wales. Ninety-one patients have been treated with CAPD at this
hospital. Ten patients were started on CAPD because they were con-
sidered relatively unsuitable for hemodialysis due to underlying vas-
cular disease (7) diabetes (2), and malignancy (1). Of these ten patients
only one survives. A decision was then made to commence all pa-
tients beginning the chronic renal failure program on CAPD and at the
same time establish an A-V fistula. This report deals with 81 patients
entered in this fashion. There were 39 males and 42 females, mean age
SD, 46.9 14 50.9 11, respectively, range 16 to 72 years. They
have been on CAPD for between 1 and 27 months. There were eight
diabetic patients (10%), two have changed to hemodialysis (HD), and
the remainder stay on CAPD. There have been no deaths in this group.
Ten of the 81 patients (12%) have been transplanted, four of whom
died. Twenty-one patients (26%) have been transferred to HD. Obe has
been transplanted, 5 died, and 15 remain alive. Seven (8.6%) died on
CAPD 40 patients (4 1%) remained on CAPD. Two patients spontane-
ously recovered renal function (ARF following angiography, RPGN)
and seven died. Sixty-two patients (76%) had one or more episodes of
peritonitis. All patients who changed to HD (21) did so because of peri-
tonitis. Of those who died on CAPD (7) six died as a result of their peri-
tonitis (one, myocardial infarct). Of those who died following transfer
to HD (5) three died as a result of failure to recover from a previously
overwhelming peritoneal infection. Life-table analysis indicates that
except for diabetic patients CAPD is less successful than hemodialysis
or transplantation.
Nutritional status of 50 patients undergoing hemodialysis. M. Aliman,
J. S. Horvath, D. J. Tiller, J. Johnson, G. G. Duggin, and B. M. Hall.
Royal Prince Alfred Hospital, Renal Unit, Camperdown, New South
Wales. Protein-energy malnutrition among patients on hemodialysis(HD) is well recognized. A nutritional assessment was carried out on
50 patients undergoing HD. There were 28 males and 22 females. Mean
age was 43 13.2 (SD), range 16 to 61 years. The mean period on HD
was 26.5 months (range, 1 to 87 months). Patients were advised to take
ito 1.5 g protein/kg bodyweight and 150 to 190 kj/kg bodyweight. Pa-
tients received multivitamins, folate, and phosphate binders. Twenty-
five patients were on in-center HD and 25 on home dialysis. The dial-
ysis times were 11 to 12 hr for center and 16 to 19 hr for home pa-
tients. The dialysate was glucose-free. An adequate diet history was
kept by 30 patients.
Parameter Nor- Nor-
SD Men mal Women mal
Bodyweight, kg
Body mass
index, kg/rn2
Triceps skin-
fold, mm
Muscle circum-
ference, cm
Protein, g/day
Home 97 46 70—84 60 20
Center 79 14 49 21
Energy, kj
Home 10179 4334 10500— 6898 2857 8700—
Center 8438 1901 13300 5204 1742 11000
Protein intakes appear to be adequate while energy intake in women
both at home and in-center falls below the recommended levels. Skin-
fold thickness was only 64% of standard for men and 88% for women.
Approximately 30% of patients undergoing HD either at home or in-
center have evidence of malnutrition.
Nutritional assessment of patients receiving CAPD. M. A. B. Thomas,
L. S. Ibels, D. C. H. Harris, J. Predergast, J. Kesselhut, and K. Heath-
cote. Royal North Shore Hospital, St. Leonards, New South Wales.
To determine if long-term CAPD is associated with significant changes
in nutritional status, anthropometric, dietary, fasting biochemical, and
hematological studies were performed monthly for up to 8 months af-
64.6 10.8 80 55.0 9.8 67
21.6 3.1 20—25 22.3 4 19—24
8.0 3.1 12 14.5 6.4 16.5
24.8 2.7 25.3 22.4 2.7 23.2
58—70
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ter commencement of CAPD in 31 patients, (23 females, 8 males), aged
14 to 64 (mean, 50) years all of whom were receiving 4 x 2 liter
exchanges/day. Results were assessed by paired Student (tests. There
was a significant (P < 0.05) increase in body weight (dry weight in-
creased 8.2%, percentage ideal weight increased 9%, weight/height2 in-
creased 11.1%) and triceps skinfold thickness (increased 30.8%) with-
out a change in maximal mid-arm muscle circumference. Dietary in-
take assessed by food record of protein and calories remained con-
stant at 1.0 0.5 g and 31 10 kcal/kg body weight/day, respec-
tively. Urine and dialysate protein losses (9.2 2.8 g/day) and urea
generation rates (208 68 mmoles/day) remained constant. There was
a significant (P < 0.05) (20%) increase in cholesterol (6.5 1.9 to 7.8
1.8 mmoles/liter) and an 11% rise in serum urea (21 4 to 24 4
mmoles/liter) with a nonsignificant rise in serum triglycerides (3.52
2.0 to 4.31 2.9 mmoles/liter). P04 (1.40 0.42 mmoles/liter), serum
albumin (37 5 g/liter), hemoglobin (95 18 g/liter), total lympho-
cyte count (2600 1400 x 106/liter) and serum transferrin (240 52
mg%) all remained constant. These results show an increase in body
fat and serum cholesterol associated with long-term CAPD, as well as
an unexplained rise in serum urea.
Deep proximal nephrons participate in the maintenance of chronic
metabolic alkalosis. B. G. Hutchison, M. S. Lucci, D. W. Seldin, J. P.
Kokko, and T. D. DuBose Jr. University of Texas Health Science Cen-
ter, Dallas, Texas. The proximal tubule has long been considered im-
portant in maintaining the metabolic alkalosis associated with con-
tracted ECF volume (MA). However, a recent study found no change
in absolute (APR) or fractional (FPR) reabsorption of total CO2 (tCO2)
in superficial proximal tubules (SPT) during MA maintained with re-
duced SNGFR. The present study assessed the tCO2 reabsorptive ca-
pacity of deep proximal nephrons (DPN) and compared this with SPT
in normal (N) (N = 31) and MA (N = 25) Wistar rats; we used micro-
calorimetry and micropuncture of loops of Henle and late SPT after
surgical losses had been replaced with isohydric plasma. Stable chronic
MA with 11% plasma volume depletion was induced by 3 to 10 days of
a chloride-free diet. DOCA, and furosemide.
SNGFR
nI/mm
APR tCO2
pmoles/,nin FPR tCO2
Right kidney
GFR
rn//mm/lOU g bw
SPT N 32 1 600 27 0.72 .02
MA 31 1 675 39 0.60 .03a
DPN N 64 6 1305 146b 0.84 .02b N 0.48 0.02
MA 60 4 2342 187ah 0.90 .0la MA 0.49 0.02
a N vs. MA 2? < 0 .02 and b SPT vs. DPN 2? < 0.001.
In conclusion, (I) chronic MA can be maintained without reduced SN-
GFR. (2) DPN of both N and MA rats have a higher tCO2 reabsorp-
tive rate than SPT. (3) DPN, but not SPT. contribute significantly to
the maintenance of MA.
Models for ion transport in early and late distal tubules of the rat kid-
ney. G. G. Allen and L. J. Barratt. Flinders Medical Centre, Ad-
elaide, South Australia. Early distal segments of the rat kidney have a
positive transepithelial pd of approximately +7 mV whereas late dis-
tal segments have a negative potential difference (pd) of approximately
—20 mV. The origin of these pds was investigated in in vivo micro-
perfusion studies. Perfusion with plasma ultrafiltrate resulted in signifi-
cantly negative mean pds of —5.4 0.7 mV and —11.3 1.9 mY in
early and late distal segments. Addition of amiloride l0 xi to this per-
fusate reduced the pds to + 1.2 0.2 mV and —3.5 0.7 mV, respec-
tively (P < 0.001). In contrast, urosemide 10 M had no effect on ei-
ther pd. Perfusion of early segments with artificial early distal fluid
yielded a positive mean pd of +2.2 0.2 mV, while perfusion of late
segments with artificial late distal fluid (ALDF) yielded a negative pd
of —24.4 2.1 mV. When the K concentration of ALDF was low-
ered from 15 to 2 mmoles/liter, the pd fell to —11.0 1.7 mY. Am-
iloride resulted in a reversal of polarity, yielding a small positive pd of
1.4 0.4mV. Meanpdsof —8.6 0.7mVand —21.8 4.OmVwere
recorded during perfusion of early and late distal segments with a low
Cl fluid ([Cl] = 7 mmoles/liter). Amiloride reduced these pds to —3.7
0.7 mV and —6.0 1.4 mY. respectively (P < 0.001). In subse-
quent experiments, the Na:K permeability ratio for early and late distal
segments was determined and found to be 0.10 and 0.07 respectively.
In conclusion, (I) the early distal positive free flow pd is generated by
inward passive diffusion of K and Na ions. (2) The late distal negative
free flow pd is probably generated by active Na reabsorption. (3) The
magnitude of the late distal negative pd appears to be inversely related
to the luminal CI concentration. (4) Both segments have a high relative
permeability to K ions.
Phosphate loading attenuates the renal tubular disorder induced by
maleic acid in the dog. H. Al-Bander, S. B. Etheredge, M. H. Hum-
phreys, and R. Curtis Morris, Jr. General Clinical Research Center,
Department of Medicine, University of California, San Francisco,
California. In the dog, maleic acid (MA) induces the renal tubular dys-
function of Fanconi syndrome/type 11 Renal Tubular Acidosis (RTA-
II). In five conscious, trained dogs undergoing water diuresis MA was
administered (20 mg/kg IV) with and without prior intravenous admin-
istration of neutral sodium phosphate solution in a dose sufficient to
raise serum phosphate to 15 mg/dl (4.8 mmoles/liter). Phosphate
loading strikingly attenuated the severity of RTA-II:
Urine flow (V)
or fractional
excretion (FE) Maleic acid
Maleic acid
with phosphate
loading P
V/GFR 11.9 1.7 (sD)% 2.3 1.5% <0.001
FE-HCO3 30.4 2.6% 9.0 1.5% <0.005
FE-K 80.0 6.3% 12.9 4.1% <0.001
FE-Na 4.9 0.64% 3.1 0.48% <0.1
Within 90 mm of initiating MA, and after the occurrence of the RTA-
II, the urinary excretion of beta-N-acetyl-glucoseaminidase (a renal
lysosomal enzyme) increased tenfold. Prior phosphate loading blunted
this increase by 68 13%. These findings provide evidence that in the
renal tubular dysfunction induced by MA, both RTA-II and a
lysosomal disorder are mediated by a phosphate-dependent metabolic
abnormality in cells of the proximal renal tubule. In light of the fact
that phosphate loading also attenuates the RTA-II induced by fructose
in patients with hereditary fructose intolerance, the current findings
suggest that a phosphate-dependent disorder of metabolism in the
proximal renal tubule may be a critical pathogenetic event in RTA-II
in a variety of clinical states.
The relative importance of vasopressin and angiotensin II for blood
pressure regulation after acute autonomic blockade in the rat. M. Hiwa-
tan, P. L. Nolan, and C. 1. Johnston. Department of Medicine, Mon-
ash University, Prince Henry's Hospital, Melbourne, Australia. The
relative importance of vasopressin (AVP) and angiotensin II (All) to
the maintenance of blood pressure after acute autonomic blockade was
investigated in conscious Long-Evans (LE) and Brattleboro
(AVP-deficient; DI) rats. After acute blockade of the autonomic
nervoussystem by atropine (1 mg/kg), propranolol (5 mg/kg) and pen-
tolinium (5 mg/kg and 10 mg/kg/hr subsequently), blood pressure (BP)
of both LE and Dl rats fell markedly, though the magnitude of the fall
in BP in Dl rats was significantly greater than in LE rats. Heart rate(HR) decreased after autonomic blockade in DI rats only. The
subsequent administration of vasopressor antagonist of AVP
(d(CH2)Tyr(Me)AVP, 2 pg/kg; VPA) produced further decreases in
BP in LE rats only, so that the BP levels did not differ between the
two strains after these treatments. A converting enzyme inhibitor (MK-
422, 10 mg/kg) further reduced BP in both strains. When the order of
administration of VPA and MK-422 was reversed, MK-422 reduced BP
in DI rats, but did not significantly change BP in LE rats. Subsequent
VPA caused a decrease in BP in LE rats only. Under the autonomic
blockade, VPA and MK-422 had no effect on HR in either strain.
Plasma levels of AVP in LE rats increased markedly after autonomic
blockade, whereas plasma A II levels were unchanged. VPA and MK-
422 administration did not affect plasma AVP levels, while plasma A
II levels were increased by VPA and decreased by MK-422. These re-
sults demonstrate that AVP plays a greater role than A II in the main-
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tenance of blood pressure after acute blockade of the autonomic ner-
vous system. This suggests that AVP is part of the overall hormonal
vasoconstrictor response to a fall in BP and that AVP and A II have
complementary roles.
Intracellular element concentrations of proximal tubules in acutely
mannitol-saline volume-expanded rats: Evidence for inhibition of the Na
pump. A. Z. Gyory, F. X. Beck, R. Rick, and K. Thurau. University of
Sydney at Royal North Shore Hospital, Sydney, Australia. Proximal
tubular Na transport is inhibited by 50% in acutely mannitol-saline vol-
ume-expanded rats but only with autologous harvested proximal fluid
suggesting the presence of a factor acting from the luminal side. This
was not due to changes in Na22 permeability which measure paracel-
lular movement of Na thus implying a direct effect of the factor on the
Na pump or the cellular entry step for Na. Intracellular element con-
centrations were measured by energy dispersive electron microprobe
analysis in mannitol-saline volume-expanded rats as prepared previ-
ously. Na, K, and Cl concentrations were (mmoles/kg wet weight) in
controls 19.3 0.8 (SE), 122.9 2.2 and 15.8 0.4 (N = 83) and in
the expanded animals 23.4 0.6 (P < 0.001), 124.2 1.3 (P < 0.5)
and 21.3 0.4 (P < 0.001) (N = 174). Percentage increases were 21,
1, and 35, respectively. Both Na and Cl were increased by more than
that due to cell shrinkage alone which was 11%. These data indicate
that the luminal Na entry step was not interfered with and that the ac-
tive Na pump itself must have been inhibited under these conditions.
Angiotensin II maintains glomerular filtration rate in experimental re-
nal hypertension. W. P. Anderson, R. L. Woods, K. M. Denton, and
S. E. Selig. Renal Laboratory, Baker tvledical Research Institute, Mel-
bourne, Australia. The role of angiotensin II has been studied in two
forms of experimental renal hypertension, renal artery stenosis and re-
nal wrap hypertension. Chronically instrumented, uninephrectomized
conscious dogs were subjected to renal artery stenosis on two occa-
sions—with and without continuous inhibition of angiotensin II con-
verting enzyme with enalapril. Over the first 2 days of stenosis, arte-
rial blood pressure rose by about 30 mm Hg when the dogs were un-
treated, and by about half that amount when they were treated with
enalapril. In a separate study, dogs were studied after 2 weeks of renal
artery stenosis and at this time there was no difference in the degree
of hypertension developed between untreated and enalapril-treated
dogs. Glomerular filtration rate (GFR) was initially decreased by about
50% in untreated dogs and by 85% in enalapril treated dogs. After 2
weeks of stenosis, GFR was normal in untreated dogs but still reduced
by about one third in enalapril-treated dogs due to decreased filtration
fraction. Bilateral renal cellophane wrapping produces arterial hyper-
tension associated with marked reductions in renal blood flow and
GFR. Continuous blockade of angiotensin II function (with enalapril)
attenuated the hypertension developed following renal wrapping in rab-
bits, and GFR fell more markedly due to reduced filtration fraction.
Thus, the main function of angiotensin II in renal hypertension ap-
pears to be the maintenance of GFR, mainly via vasoconstriction of
postglomerular blood vessels.
Disturbed renal microanatomy in bromoethylamine hydrobromide
(BEA) induced chronic papillary necrosis in the rat. C. H. Burger, R.
B. Cross, and G. Gobe. Department of Physiology and Pharmacol-
ogy, University of Queensland, St. Lucia, Australia. Disturbances of
renal vascular-tubular relationships were studied after papillary ne-
crosis (RPN) was induced in 16 male Sprague-Dawley rats. Single sub-
cutaneous injections of Bromoethylamine Hydrobromide (BEA-250
mg/kg) were used for both groups of acute (3 days) and chronic (1 to 3
month) specimens. After in vivo fixation, colored silicone rubber was
perfused into the renal circulation. The tissue was cut into thick sec-
tions, cleared, and mounted under a photomicroscope for tubular mi-
croinjection. This technique permits simultaneous visualization of the
entire nephron and its associated microvasculature. Cortical scarring
and renal papillary necrosis (RPN) were observed in the chronic speci-
mens. In these the papilla were deleted at the level of the inner-outer
medullary border. Reduced populations of juxtamedullary glomeruli
accounted for the narrowed cortex. Surviving j uxtamedullary glomeruli
gave rise to unusually profuse and dilated interbundular capillary net-
works within the outer medulla. An increased incidence of aglomeru-
lar vasa recta arising from arcuate arteries was also observed. Tubular
microinjections in the superficial, mid, and juxtamedullary cortex re-
vealed otherwise normal vascular-tubular relationships. It was not pos-
sible to inject contrast medium into tubules associated with more than
40% of visible juxtamedullary glomeruli. This suggests that these neph-
rons were occluded by RPN. Only short-looped nephrons were found
in the outer medulla. This is consistent with the view that only the
long-looped nephrons were deleted in RPN.
Acute volume expansion: Proximal tubular Na transport inhibition by
autologous tubular fluid without changes in permeability. A. Z. Gyory
and W. Willis. University of Sydney at Royal North Shore Hospital,
Sydney, Australia. A considerable amount of experimental work has
narrowed the possible explanation for the natriuretic effect of acute
volume expansion to either physical forces or a humoral agent. How-
ever, other factors controlling Na transport perturbed by attempts to
demonstrate a humoral agent, have denied ready acceptance of its ex-
istence. Steady state transepithelial concentration differences of Na (
cNa) and permeability (PNa) (Na22) were measured in proximal tu-
bules of rats in the nonexpanded (NE) and subsequent volume-ex-
panded (VE) state with mannitol-saline. For tubular injections either an
artificial solution (AS) or harvested proximal tubular fluid (HF) both
containing mannitol were used. cNa (mmoles/kg) was significantly
reduced (P < 0.0001) with HF (9.1 1.1; SE 31) when compared AS
both during VE (18.2 1.0, 40) and NE (17.4 1.0, 37) and when
compared to HF in NE (22.4 1.4, 26). PNa (x l05mm2sec) was
relatively constant at 7.3 1.2, 7.7 0.8, 8.6 1.1, and 8.1 1.1,
respectively. Due to methodology employed these results provide un-
equivocal evidence for a factor present in proximal tubular fluid of VE
animals only, which inhibits Na transport without altering transepithe-
hal PNa which would have had to be increased by an equivalent
amount to explain the decrease in cNa, pointing either to an effect
on the cellular Na entry step or the Na pump itself.
Antihypertensive therapy in pregnancy. E. D. M. Gallery and A. Z.
Gyd,y. Department of Renal Medicine, Royal North Shore Hospital,
and University of Sydney's Department ofMedicine at Royal North
Shore Hospital, Sydney, Australia. Hypertension, whether chronic or
pregnancy-associated, is the most common medical complication of
pregnancy, It is associated with much maternal and perinatal morbid-
ity, which can be reduced by antihypertensive therapy. The principle
reason for exhibiting antihypertensive therapy is to prolong pregnancy
in the interests of the fetus, therefore the most appropriate agent to use
is one which will have potential advantage for fetal welfare. We pre-
viously reported preliminary results from a prospective randomized
comparison of methyldopa (M) and oxprenolol (0) for therapy; this re-
port deals with the completed study, involving 169 women, 83 allo-
cated to M, and 86 to 0. All subjects had a pretreatment sitting dias-
tolic BP above 90 mm Hg and all completed at least 7 days of therapy
prior to delivery. There were no differences in height, weight, age, or
parity. They were comparable in duration of therapy prior to delivery
[M 8.2 1.1,08.9 1.3 (weeks sEM)], duration of pregnancy [M
38.4 0.2, 0 38.1 0.3 (weeks SEM)], and severity of hyper-
tension (M'47/97 '/1.l mm Hg, O'/99 2/08 mm Hg). Control
of hypertension was the same in both groups. Pregnancy outcome was
significantly better in those treated with 0, with higher overall birth
weights (M 3002 83 g, 0 3216 61 g, P < 0.001) most marked in
those with pretreatment diastolic BP above 95 mm Hg (M 86.3 3.6%
of normal for gestational age, 0 96.5 2.3% N, P < 0.01), and mul-
tigravid (M 92.3 8.0% N, 0 99.2 3.5% N, Ns) pregnancies, al-
though more marked in the former. The occurrence of fetal distress (fe-
tal heart rate monitoring) was significantly more common in M (12%)
than in 0 (3%) (K2 = 4.358, P < 0.05). We conclude that therapy with
oxprenolol has specific advantages for fetal well being in hypertensive
pregnancy and should be used in preference to methyldopa if there is
no maternal contraindication.
Renal function deterioration following angiotensin converting enzyme
inhibition in hypertension due to renal artery stenosis. B. Jackson, L.
Arnolda, P. G. Matthews, B. McGrath, and C. I. Johnston. Hyper-
tension Service and Monash University Department of Medicine,
Prince Henry's Hospital, Melbourne, Australia. Angiotensin convert-
ing enzyme inhibition has been reported to cause an acute deteriora-
tion in renal function in some patients with renovascular hypertension.
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To delineate those patients with renovascular hypertension who are at
risk, we have reviewed 30 patients with renovascular hypertension
treated with captopril for I week or more. Eight episodes of acute re-
nal insufficiency were seen in six patients. Serum creatinine rose pro-
gressively to at least twice the pretreatment value following the intro-
duction of captopril, and fell immediately following its cessation. In all
eight episodes serum creatinine returned to pretreatment levels. The
acute rise in serum creatinine was not related to the degree of hypo-
tension following captopril, nor concurrent diuretic treatment. We
have not seen this complication of captopril treatment in any patient
with essential hypertension. Patients were grouped according to the na-
ture of their renovascular disease into (1) unilateral renal artery sten-
osis (II patients), (2) bilateral renal artery stenosis (11 patients), (3)
single kidney with renal artery stenosis (3 patients), and (4) transplant
renal artery stenosis (5 patients). Of patients who developed renal func-
tional deterioration three had bilateral renal artery stenosis, one a sin-
gle kidney with renal artery stenosis, and two stenosis of a transplant
renal artery. Renal functional deterioration was not detected in any
case with unilateral renal artery stenosis. Patients who developed acute
renal failure had more severe pre-existent renal disease (mean pre-
treatment creatinine 251 46 smoles/liter) than those who did not (153
21 iimoles/liter). Daily dose of captopril was lower in those who de-
veloped renal failure (140 mg/day, compare 350± 150 mg/day). We
conclude that the patient with renovascular hypertension who is at risk
of renal functional deterioration following captopril treatment has a sin-
gle functioning kidney (native or transplant) with renal artery stenosis,
or bilateral renal artery stenosis, and has significant pre-existent renal
failure. Although renal functional deterioration was confined to these
specific clinical groups, it was not an invariable complication.
Effect of ACTH administration on urinary kallikrein excretion in hu-
mans. J. A. Whitworth, B. H. Van Leeuwen, M. C. Hannah, B. A. Scog-
gins, and R. Thatcher. Department of Nephrology, The Royal Mel-
bourne Hospital, Monash University Department of Medicine, Prince
Henry's Hospital, Victoria, Department of Medicine, Royal Mel-
bourne Hospital, and Howard Florey Institute of Experimental Physi-
ology and Medicine, University of Melbourne, Melbourne, Australia.
The effect of ACTH administration (1 mg/day for 5 days) on urinary
kallikrein excretion and its relationship to changes in plasma and urine
electrolytes, renin concentration (PRC) and steroids was examined in
six normotensive and six mildly hypertensive subjects. PRC was mea-
sured using a modification of the antibody capture technique of Poul-
sen and Jorgenson and plasma aldosterone and deoxycorticosterone by
double isotope derivative dilution assay. Urinary kallikrein activity
was measured by incubating urine with partially purified dog plasma ki-
ninogen at 37°C and measuring generated bradykinin using a radio-
immunoassay specific for lys-bradykinin. ACTH administration pro-
duced hypokalemia, initial urinary sodium retention, a fall in active
plasma renin concentration, a transient rise in plasma aldosterone con-
centration and sustained rises in plasma deoxycorticosterone concen-
tration and urinary kallikrein activity. Changes in patients with mild
hypertension were similar in pattern to normotensives, but urinary kal-
likrein concentration were lower. The effects of ACTH on urinary kal-
likrein excretion appeared to be independent of aldosterone and cor-
related most closely with deoxycorticosterone concentrations (F = 6,
529, P < 0.02).
Renal artery digital subtraction radiology: An outpatient investigation
for renovascular hypertension. B. Jackson and L. Dugdale. Renal Serv-
ice and Division of Organ Imaging, Queen Victoria Medical Centre,
Melbourne, Australia. We have assessed the adequacy and conven-
ience of the digital subtraction radiographic procedure (using a Diason-
ics DF100) as a screening test for renal artery stenosis. Fifty-six se-
quential studies (in 54 patients) were reviewed from patients referred
for investigation of hypertension. The age of the patients ranged from
IS to 75 years and serum creatinine from 50 to 810 tmoles/liter. Con-
trast (Conray 280 or Urografin 76%) was injected as a bolus via a cen-
trally placed venous catheter (43 studies) or via a small (5 French) ar-
terial catheter (13 studies). For venous studies total contrast injected
averaged 37 2 ( sEM) g iodine and for arterial injections 17 2
g iodine. There were three adverse experiences (two contrast re-
actions and one venous extravasation). Patients tolerated the proce-
dure well and were fully mobilized one (venous) or 2 hr (arterial fol-
lowing the procedure. Of the 56 studies 4 were judged as inadequate.
Failure to clearly visualize the main renal arteries was associated with
movement of bowel gas, patient movement, and obesity. All failures
occurred with the venous injection technique. Of the 52 studies judged
as technically adequate 40 showed normal renal arteries. Renal vein re-
nm studies were available in nine of these and were all normal. DSA
revealed renal artery lesions in nine patients. In five of these, renin
studies confirmed significant renal artery stenosis which was subse-
quently successfully treated by surgery (three) or captopril (two). Of
the remaining four patients, two had renal artery obstruction progress-
ing to uremia, one had mild bilateral fibromuscular disease (confirmed
by conventional angiogram) and one has not been further investigated.
We conclude that digital subtraction renal arteriography is a useful in-
vestigation in patients with a suspected renovascular hypertension.
The major advantage over conventional angiography is the outpatient
basis of the investigation.
Ketanserin in acute management of severe hypertension. B. F.
Murphy, J. A. Whitworth, and P. Kincaid-Smith. Department of
Nephrology, The Royal Melbourne Hospital, Melbourne, Australia.
Ketanserin is a 5HT2 antagonist with alpha adrenoreceptor-blocking
activity. This study examines the efficacy and safety of ketanserin in
the control of severe primary and secondary hypertension, including
renal hypertension. Patients with uncontrolled hypertension were ad-
mitted to the hospital and entered the study if the supine diastolic blood
pressure phase V (SDBP) was greater than 110 mm Hg after 2 hr con-
tinuous BP monitoring (DINAMAP). Ketanserin was administered as
an intravenous (i.v.) 5 mg bolus every 60 sec until SDBP fell to greater
than 15 mm Hg or maximum dose (30 mg) was reached, then by iv.
infusion at 4 to 20 mg/hr to maintain SDBP fall to greater than 15 mm
Hg over 6 hr. Fourteen patients were monitored and nine (one man,
eight women, age 18 to 64) fulfilled the entry criteria. Eight of nine
were on antihypertensive medication, and eight had underlying renal
disease. Pre-injection mean BP was 187/121 mm Hg for these nine pa-
tients, falling at 5 mm to 178/101 mm Hg and at 10 mm to 160/100 mm
Hg. SDBP fell to greater than 15 mm Hg in seven of nine patients. BP
remained satisfactorily controlled over the 6 hr ketanserin infusion and
for a further 24 hr. Heart rate was unchanged. Side effects were vom-
iting (one), dizziness (one), and dry mouth (one). There were no
changes in ECG, blood glucose, plasma creatinine, or electrolytes. The
two patients who did not respond were receiving the alpha blocker pr-
azosin but three other patients on high dose prazosin did respond. We
concluded that iv. ketanserin is safe and effective in the acute man-
agement of severe hypertension, including hypertension secondary to
renal disease.
A controlled trial comparing clonidine hydrochloride and alpha meth.
yl dopa in pregnant women with hypertension. J. S. Horvath, A. Phip-
pai-el, A. Korda, D. Henderson-Smart, A. Child, G. G. Duggin, B. M.
Hall, and D. J. Tiller. Royal Prince Alfred Hospital, Camperdown,
New South Wales. One hundred pregnant women with elevated blood
pressure were randomized to receive clonidine hydrochloride (C) or al-
pha methyl dopa (A) for the treatment of hypertension. Patients were
entered into the trial if on two or more occasions they had elevated
blood pressure; mean arterial pressure (MAP) in excess of 100 mm Hg.
Patients were commenced on comparable doses of C or A and the dose
was increased to maintain MAP less than 100 mm Hg. There was no
difference in age (29.9 6.2 and 28.1 5.9 years), renal function, par-
ity, level of serum uric acid, or gestation before treatment (31.1 8.2
and 32.5 7.0 weeks) between patients who received C or A. The pre-
treatment MAP was the same for each group (114 13.8 and 117
2.3 mm Hg) and there was a similar reduction in MAP in each group
(98 9.2 and 101 7.4 mm Hg). Six patients in each group required
the addition of a vasodilator. Gestation at delivery was the same for
both groups (C:37.4 2.8 and A:36.6 3.6 weeks). The birth weights
were similar (2.78 0.93 and 2.63 1.62 kg) and the neonatal sur-
vival was 98% in each group. The blood pressure of the neonates in
each group was the same (C:34 8.2 and A:31 10.6 mm Hg) and
these values are comparable to those in neonates of mothers who had
not received antihypertensive agents. Clonidine hydrochloride is a safe
and effective antihypertensive agent for use in pregnancy and may be
used as an alternative for alpha methyl dopa.
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Aluminum and azotemic osteodystrophy in patients requiring main-
tenance dialysis. T. Furlong, Y. L. Chan, A. C. A/frey, J. F. Mahony,
and S. Posen. Renal and Endocrine Units, Royal North Shore Hos-
pital, St. Leonards, New South Wales. Iliac crest bone biopsy speci-
mens were obtained from 94 patients aged 17 to 69 years who had been
receiving dialysis for I month to 11 years. Eighty-five patients were on
hemodialysis and nine on peritoneal dialysis. Aluminum hydroxide (1.8
to 19.2 g/day) was prescribed in all patients but one. Quantitative bone
histomorphometry was abnormal in each patient. 1-lyperpara-
thyroidism was the dominant lesion in 18 patients, osteomatacia in 26,
while 50 patients had mixed lesions. The mean duration of dialysis was
1.2 1.1 years in patients with hyperparathyroidism and 3.8 2.5
years in patients with mixed lesions. There was a positive correlation
between the duration of dialysis and the fractional osteoid area (r =
+0.397, P < 0.001). Bone aluminum concentrations measured by
graphite furnace and atomic absorption spectrometry were higher in
patients with mixed lesions than in patients with osteomalacia or
hyperparathyroidism. Bone aluminum concentrations correlated posi-
tively with the duration of dialysis (r = +0.420, P < 0.00 I) and with
fractional osteoid areas (r + 0.275, P < 0.05). The total quantities
of aluminum compounds prescribed correlated positively with the du-
ration of dialysis (r = +0.452, P < 0.001) but with neither bone alu-
minum concentrations (r = + 0.239) nor fractional osteoid areas (r =
+0.061). It is concluded that aluminum accumulation in bone of pa-
tients on chronic dialysis possibly contributes to the development of
osteomalacia. Patients with pure osteomatacia do not necessarily suf-
fer from aluminum intoxication. Oral aluminum phosphate binders do
not appear to be a major source of aluminum.
Bone "buffering" capacity in aluminum associated bone disease
(AABD). B. U. IhIe, M. Cochran, G. Becker, D. Campbell, and P. Kin-
caid-Smith. Department of Nephrology and Biochemistry, Royal Mel-
bourne Hospital and Flinders Medical Centre, Melbourne, Australia,
AABD has been shown to relate to bone accumulation of aluminum
(Al) in a concentrated amount at the bone-osteoid junction. Binding of
Al to the mineralization front may form a barrier to the further depo-
sition of Ca. This may account for the tendency to hypercalcemia fre-
quently observed in these patients. Patients with AABD show histo-
logical lack of hyperparathyroidism with a normal or only slightly el-
evated PTH. Thus, there is most likely a difference in bone turnover
states between patients with osteitis fibrosa and those with AABD.
Calcium infusion studies were performed in six patients with biopsy
proven AABD compared to six patients with known hyperpara-
thyroidism (HPTH). Three normal controls were also studied. Cal-
cium was infused at a constant rate. The mass of Ca required to pro-
duce the initial rise in [Ca] tells us the notional poo1 size (Vo liters) at
time 0. Vo Ca for each interval gives us the expected mass of Ca to
account for the observed rise. The actual mass of Ca infused for that
interval is known and found to exceed the expected amount. This ex-
tra amount of Ca can be considered to have been "buffered." The
slope of the rate of removal on the [Ca] gives Ca clearance. It was
found that patients with AABD had, as a group, approximately 30% di-
minished clearance of Ca compared to normal controls. Patients with
proven HPTH had a 20% greater clearance rate than normals. Patients
with AABD have a diminished buffering capacity to acute changes [Ca]
and hypercalcemia in chronic renal failure patients may be suggestive
of AABD and not HPTH.
The kinetics of chelation of Al, Zr, and Fe by DFO. R. A. Odell, P.
C. Farrell, D. J. Brown, J. K. Dawborn, S. M. Evans, and W. F.
Heale. Centre for Biomedical Engineering, University of New South
Wales, Sydney, Renal Unit, Austin hospital, Heidelberg, Victoria,
Australia. Among the consequences of Al intoxication are dialysis os-
teomalacia, dementia, and anemia. Alleviation of the symptoms of Os-
teomalacia and dementia with desferrioxamine (DFO) is presumed to
be due to Al chelation but Fe and Zr are also chelated by DFO. Che-
lation is rapid, can be observed during dialysis, and the kinetics bear
on the therapeutic and investigative use of DFO. DFO (4 to 6 g) was
infused via the venous tine over the first 1.5 hr or last 4 hr of dialysis.
Ultrafiltrate (UF) was collected before (A) and after (B) this dialysis
and before (C) the next dialysis using positive pressure ultrafiltration.
In some patients UF was collected throughout dialysis via an in-line
ultrafilter (Amicon). DFO was measured by a colorimetric assay, Zr
and Fe by inductively coupled plasma emission spectrometry, and Al
by furnace atomic absorption spectometry. Results were: (I) The DFO
concentration drops sharply when infusion stops indicating a reversal
of the gradient between intra and extravascular spaces. Estimation of
the distribution volume and metabolic clearance would require a two-
pool model (at least). (2) Zr was seen in all sorbent dialysis patients,
UF(CA) = 70.5 9.5 smoles/1iter (N = 11). It was not seen in two
single-pass patients, zZruF<O.l moles/liter. ZrUF reaches a plateau 1
to 2 hr after start of infusion (N 3). (4) The Al pattern was variable
with a decreasing slope or even plateau toward the end of dialysis. Re-
sponses of these metals to DFO differ, reflecting, for example, chemi-
cal form and accessibility. There may be two pools of a metal (Al, Zr)
and the amount chelatable at one time from some pools (Zr, Al) may
be limited. This would affect a dose-response curve.
Comparison of plasma, red cell, and hair aluminum in patients on he-
modialysis and continuous ambulatory peritoneal dialysis. E. McGinley,
B. J. Stevens, N. Biddle, N. M. Thomson, and R. C. Atkins. Depart-
ment of Nephrology, Prince Henry's Hospital, Melbourne, Australia,
Aluminum (Al) accumulates in patients on maintenance hemodialysis
(HD) and continuous ambulatory peritoneal dialysis (CAPD). Alumi-
num toxicity correlates with plasma Al levels which is associated with
excessive oral intake of Al in the form of aluminum hydroxide
[Al(0H3)1 and the exposure to Al in dialysing fluids. It has been sug-
gested that Al levels are less in CAPD patients because of less expo-
sure to Al in dialysate, and to the lower requirements for oral Al(OH)3
as a phosphate binder. We compared plasma Al as well as red blood
cell (rbc) and hair At in 25 patients on CAPD, 20 patients on HD, 8
chronic renal failure patients on oral Al(OH)3, and 97 normal controls.
Aluminum was measured on a Varion Techtron AA—5 atomic absorp-
tion spectrophotometer. Plasma Al levels were significantly elevated in
alt patient groups {mean SD plasma Al (motes/titer) were controls
0.33 0.2; HI) 4.44 2.3; CAPD 4.5 3.0; CRF 1.94 l.2}. Red
cell Al levels were similarly elevated in each of the groups (mean rbc
Al (tg/l0'2 cells) were controls 0.9 1.0; HD 7 5.9; CAPD 8
8.2; CRF 2.3 2.8}. Plasma and rbc Al results were not statistically
significantly different between the HD and CAPD groups. The HD pa-
tients were on dialysis therapy for a longer period (mean time on dial-
ysis in months HD 38.6; CAPD = 17.7), and were on higher doses
of Al (dose of AIOH g/day HD 9.3 4.6; CAPD 7.0 3.6) for a long-
er period of time (mean time on Al(OH)3 months HD 38 20; CAPD
24 25). The CAPD group was slightly older (mean age in years
CAPD 50 17; HI) 40 36) and included five diabetic patients. Hair
Al levels were not statistically significantly different from the controls
in any of the groups {mean hair Al (sgIg) were controls 8.9 7.12;
HD = 9.1 7.4; CAPD = 10.9 II; CRF = 10.64 6.56). We con-
clude that plasma and rbc Al was significantly elevated in patients on
CAPD as welt as in patients on HD and that there was no significant
difference between the groups. CRF patients on oral Al(OH)3 also had
significantly elevated levels of plasma and rbc Al, but their levels were
much tower than the dialyzed group. Hair At was normal in HD and
CAPD patients and did not correlate with either plasma or red cell Al
levels.
Aluminum binding by transferrin in plasma of maintenance dialysis
patients. M. Cochran, I). Patteron, and J. H. Coates. Flinders Medi-
cal Centre, AMDEL and University of Adelaide, Adelaide, South Aus-
tralia. Small concentrations of aluminum in dialysis fluid contribute to
toxicity in maintenance hemodialysis patients as the result of uptake
of aluminum by plasma, apparently against a concentration gradient.
The protein binding that is implied, has been investigated using gel fil-
tration. With carefully minimized background aluminum, gel filtration
of plasma with Sephacryl-300 reproducibly shows a single aluminum
peak corresponding exactly to the position of transferrin and distinct
from that of albumin, the other major protein at this elution volume.
The mean SE aluminum/transferrin molar ratio in adjacent fractions
from replicate experiments was constant (0.12 0.006), whereas the
association with albumin was variable. The effect could be mimicked
with human transferrin in buffer containing trace amounts of alumi-
num. When samples of plasma were treated with equivalent amounts
of antitransferrin globulin, the bound aluminum demonstrable in con-
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(N = 6) 7.23 0.26 0.78 0.04
(N = 7) 7.37 0.77 0.92 0,04*
0.13 0.01tt
0.19 0.Olt
trol samples was removed in the precipitate. To find the number of
binding sites for aluminum on the transferrirt molecule, samples of a
solution of purified transferrin were treated with a range of concentra-
tions of aluminum and the free aluminum determined after ultrafiltra-
tion on an Amicon membrane. At aluminum/transferrin ratios below 2,
17.8 1.5% of aluminum was free, compared to 71.0 2.9% when
the ratio exceeded 3, indicating there are two binding sites for alumi-
num on the molecule. Competitive inhibition by aluminum of ferric iron
uptake, allowed an estimate of the effective affinity constant, given the
value for the iron-transferrin affinity constant. The binding of alumi-
num to transferrin was only 200-fold weaker than for iron, with
pK=21. Transferrin appears to be the sole aluminum binding protein
in plasma, and our findings explain the observed avidity of plasma for
the metal.
Polyvalent ions in the etiology of dialysis bone disease and encepha-
lopathy and response to de-ionization. A. G. Hocken, B. B. Berkley, and
N. D. Morrison. Dunedin Public Hospital, Dunedin, New Zealand.
Two subgroups of patients on long-term (2'12 to 10 years) hemodialysis
are considered. Three individuals were on center dialysis in the new
hospital building and two at home. With this exception. both groups of
patients were comparable in all clinical and technical considerations,
including the long-term use of the same community water supply,
which had been aluminum-treated since 1975. All showed dialysis bone
disease—vitamin D sensitivity. osteomalacia, periarticular calcifica-
tions, and myopathy. Only the group receiving center dialysis became
encephalopathic. This was attributed to the heavy, nonaluminum, poly-
valent ion contamination of the water conduit system of the new build-
ing. Consideration is given to the interaction of bone calcium metabo-
lism, aluminum adsorption and polyvalent ion content of the center wa-
ter supply with their effects on Vitamin D sensitivity and the precipi-
tation of encephalopathy by aluminum displacement. The present
study demonstrates the clinical, biochemical, radiological, and histo-
logical alleviation of bone and joint disease following the introduction
of deionized water. it also shows that while the encephalopathy im-
mediately ceased to progress under this circumstance, its clinical mani-
festations persist and have not remitted, it is concluded that while dial-
ysis bone disease is correctable by treatment, encephalopathy, while it
may be arrested, cannot be cured.
The effects of PGE2 and converting enzyme inhibition on the rat renal
microcirculation. G. K. Harvey and R. B. Cross. Department of Physi-
ology and Pharmacology, University qf Queensland, St. Lucia, Aus-
tralia. The intrarenal effects of PGE2 infusion during captopril induced
angiotensin I converting enzyme inhibition (CEI) were studied in the
isolated perfused rat kidney. Preliminary experiments revealed that
PGE2 infusion alone is vasoconstrjctor to the renal circulation at a dose
of 5 ng mm -. Captopril (100 zg mm - I) was infused 1 mm prior to and
during 3-mm infusions of PGE2 (0.1, 5. 100 ng min1). Regional flow
rates, estimated by the timed uptake of 251 serum albumin, are pre-
sented in the table:
Perfusate flow rates, ml g' min' (mean SE)
Outer
Total flow medulla Papilla
None of the infusions had any effect on total flow. CEI caused a de-
crease in papillary flow. PGE2 infusion during converting enzyme in-
hibition was selectively dilator to the outer medulla. These intrarenal
dilator properties appear to be under certain conditions masked by the
effects of augmented renin release,
Renal blood flow in experimental congestive heart failure in rabbits.
M. Cocks, L. Arnolda, B. McGrath, and C. I. Johnston. Prince
Henry's Hospital, Melbourne, Australia. In congestive heart failure
(CHF) a series of vasoconstrictor mechanisms are activated resulting
in a raised peripheral resistance and a redistribution of blood flow. Al-
terations in renal blood flow (RBF) may play a role in the salt and wa-
ter retention that occurs in this syndrome. A chronic cardiomyopathy
resulting in CHF was produced in rabbits by the chronic administra-
tion of adriamycin (1 mg/kg intravenously twice weekly for 10 weeks).
These animals developed a cardiomyopathy with extensive fibrosis,
cardiac dilatation, and hypertrophy. Fluid retention also occurred with
both pleural effusions and ascites. Cardiac output (measured by ther-
modilution) progressively decreased at 8 and 12 weeks. Blood pres-
sure also showed a small flow. RBF was measured by a radioisotopic
clearance technique using 251-hippurate in controls and adriamycin
treated rabbits at 8 and 12 weeks. It also fell progressively in the rab-
bits with congestive cardiomyopathy at 8 and 12 weeks. Plasma levels
of renin, vasopressin, and catecholamines were also measured at 0, 4,
8, and 12 weeks. There was evidence of early activation of the renin-
angiotensin system with clearly elevated renin levels at 8 weeks and a
further rise by 12 weeks. In contrast catecholamine levels did not in-
crease. RBF is decreased early in an animal model of chronic myocar-
dial failure. There was a concomitant increase in renin and vasopres-
sin. These vasoconstrictor hormones may be responsible for some of
the increase in renal vascular resistance and hence the fall in RBF. To
evaluate their role specific antagonists to angiotensin and vasopressin
have been administered to rabbits with heart failure.
Relationship between vascular responsiveness to angiotensin II and sys-
temic vascular resistance in primate pregnancy. A. F. Phippard, I. S. Hor-
vat/i, M. G. Garner, E. M. Glynn, P. 1. Fletcher, G. G. Duggin, B. M.
Hall, and D. J. Tiller. Royal Prince Alfred Hospital, Camperdown, New
South Wales. As systemic vascular resistance (SVR) is inversely pro-
portional to r4 (r=vessel radius), a decrease in SVR—as is character-
istic of pregnancy—should result in reduced vasoconstrictor re-
sponses. We have examined the relationship between SVR in early
primate pregnancy and systemic vascular responsiveness to infused
angiotensin II. Hemodynamic studies including cardiac output (CO, ther-
modilution), right atrial pressure (RAP), and systemic arterial pressure(SAP. femoral catheter) were performed in six baboons (Papio
hamadryas) before and during pregnancy. For dose-response studies of
the rise in SVR (dSVR), All was infused at four doses (0.01, 0.03, 0.06,
and 0.10 g/kg/min) in a random order. Plasma renin activity (PRA)
was also measured. Results (mean P < 0.05):
Control (N = 13) 7.44 0.35 0.78 0.06 0.26 0.02
CEI, 100g min' (N = 8) 6.73 0.43 0.76 0.06 0.17 0.O2tt
CEI +
PGE2
0.1 ng
mm -
5 ng
mm'
100 ng
nun'1 (N 6) 7.27 0.55 0.97 0.04*t 0.13 0.01ff
Significant difference from control tP < 0.05 ttP < 0.01
Significant difference between CE! and CEI + PGE2 < 0.05
< 0.01
Gestation Nonpregnant 4 Weeks
Mean SAP, mm Hg 105 7 103 10
CO, liters/mm 1.67 0.11 1.86 0.14*
SVR, SAP-RAP/CO 60.5 7.6 54.3 6.6*
PRA, fm/liters/sec 486 136 1450 386*
Dose-response curve slope
dSVRJlogAll 12.7 11.2
Gestation 6 Weeks 8 Weeks
Mean SAP, mm Hg 96 7 89 10*
CO, liters/mm 1.88 0.06* 1.92 0.09*
SVR, SAP-RAP/CO 49.3 5.1* 45.0 5.1*
PRA,fm/lizers/sec 1331 669* 1056 285*
Dose-response curve slope
dSVR'logAlI 8.6 9.4
There was a significant fall in SVR from 4 weeks and linear regression
analysis showed a significant relationship for dSVR/logll dose with
SVR (r=0.9) but not with PRA. The results are consistent with the pre-
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dicted effect of reduced SVR on vascular responsiveness in early
pregnancy and indicate that the increased pressor response to All early
in pre-eclamptic pregnancy may be associated with increased SVR prior
to the onset of hypertension.
Potassium excretion by the isolated perfused rat kidney following po-
tassium adaptation. W. R. Adam and B. A. Adams. Renal Unit, Re-
patriation General Hospital, W. Heidelberg, Australia. Adaptation to
a high potassium diet leads to an enhanced ability to excrete an acute
potassium load. This study looks at whether the enhanced kaliuretic
ability is an intrinsic renal adaptation or is secondary to extra renal me-
diators, such as aldosterone. Kidneys were perfused in a cell-free albu-
min medium with glomerular filtration rates of 0.5 0.1 mllmin and
fractional sodium reabsorption of 95 2.3%. The diets contained ei-
ther 10 mmoles/l00 g or 140 mmoles/l00 g of potassium. Feeding in the
24 hr prior to perfusion had a profound effect on fractional K [(fed
1.4 0.11) (N = 15) fasted 0.70 0.07 (9) P < 0.01) but not control
K (fed 0.59 0.05) (9) fasted 0.64 0.05 (8) P > 0.05] rats. After
feeding, but not fasting, high K rats had a greater fractional K ex-
cretion than control K rats (P < 0.01). While a small intrinsic renal
adaptation in potassium excretion has not been absolutely excluded, a
major component of potassium adaptation relates to changes associ-
ated with feeding. These nonrenal adaptative changes are likely to re-
late, at least in part, to effects of aldosterone as fractional K excre-
tion in rats fed high K- is inhibited by the aldosterone antagonist,
spironolactone [1 mg/l00 g and 106M in medium) (fractional K ex-
cretion, high K 1.45 0.18 (10) high K + spiro 0.95 0.15 (4) P
<0.01].
Mechanisms of renal excretion of cisdichlorodiamine platinum. R. Ca-
terson, S. Etheredge, P. Snitch, and G. Duggin. Sydney Hospital and
Royal Prince Alfred Hospital, Sydney, Australia. Experiments were
done to demonstrate the clearance of nonprotein bound free platinum
in diuretic rabbits and to determine whether the platinum complex was
secreted by either the cationic or anionic system of the proximal tu-
bule of the kidney. Eighteen diuretic rabbits were given cisdichlorodi-
amine platinum (CDDP) and the clearance of plasma water platinum
was determined with a simultaneous inulin clearance. The rabbits were
then given probenecid (50 mg/kg) or choline (50 mg/kg) and the clear-
ance of free platinum was calculated. Platinum analyses were per-
formed on an atomic absorption spectrophotometer in connection with
a fiameless atomization furnace. No significant difference was found in
the mean glomerular filtration rate (GFR) before or after CDDP was
given. The mean GFR of the total group of collections was 8.9 4.0
ml/min; the mean GFR following probenecid given first was 8.6 2.9
mI/mm. There is an inverse curvilinear relationship between plasma
platinum and clearance of platinum corrected for GFR, (Cplat/GFR).
Platinum is secreted by the tubule, as the mean Cplat/GFR before any
drug was given was 12.5 3.9. The secretion of platinum was not af-
fected by choline Cplat/GFR being 10.8 2.2 (no significant differ-
ence), but probenecid blocked platinum secretion with Cplat/GFR af-
ter probenecid being 3.9 0.5 (P < 0.005). Therefore, platinum com-
plex is secreted by the anionic system.
Use of diuretics to study salivary secretion. R. D. Wright, J. R. Blair-
West, and J. F. Nelson. Howard Florey Institute of Experimental
Physiology and Medicine, University of Melbourne, Victoria, Aus-
tralia. Saliva is formed by the secretion of an isotonic high [Na'-], low
[K'-] primary fluid in the endpieces which is altered by reabsorptive
and secretory mechanisms in the striated ducts. tn view of analogies
in the formation of saliva and urine we studied the effects of diuretic
agents and ouabain on oxygen usage, ionic transfers, and salivary flow
when infused into the arterial blood supply (10-8 to l0- M in blood)
of the vascularly isolated parotid glands of anesthetized sheep and al-
lowed to recirculate. In Na repletion, amiloride, furosemide,
ethacrynic acid, chlorothiazide, and acetazolamide had little effect on
flow rate or ionic composition. Ouabain (at 105M) affected only
HCO3 and Cl restoring them to plasma levels and reduced 02 usage
to one-third control. Acetazolamide reduced (HC03) by 10%. In Na
depletion, ouabain at 10 M increased salivary [Na'-] from 103 3
to 160 4 mat, decreased [K] from 54 3 to 10 2 mat, caused
HC03 and Cl- to approach plasma levels, increased osmolality from
257 I to 294 8 m0sm/kg, and reduced 02 usage as in Na reple-
tion without significant effect on salivary flow. Amiloride had a similar
but smaller effect on [Na'-], [K'-], and osmolality without effect on
oxygen usage or salivary flow. Furosemide, ethacrynic acid and chlo-
rothiazide had no effects on salivary composition or flow although the
systemic levels caused diuresis and natriuresis. The results indicate
that the agents which inhibit: (1) cotransport of Na'- and Cl—, (2) Na,
K-ATPase, (3) Na permeation of the luminal membrane, (4) carbonic
anhydrase, do not significantly affect flow rate in this gland, at the high
doses used. The striated duct responses resemble those of the distal tu-
bule.
An assessment of compensatory renal function and iothalamate clear-
ance in sheep. L. J. Filippich, P. B. English, and J. Ainscow. Depart-
ment of Veterinary Medicine, University of Queensland, St. Lucia,
Australia. Both compensatory renal function and sodium iothal-
amate°5 clearance were studied in four adult Merino ewes after re-
ductions in functional renal mass. Renal clearances of inulin (C1), io-
thalamate (C0), and p-aminohippuric acid (Cpah) were used to deter-
mine renal function before and then 7 and 170 days after 50 and 75%
renal mass reductions. The renal mass reduction to 50% of normal was
achieved by total ligation of the right renal artery, and to 25% of nor-
mal by also ligating branches of the left renal artery. Both C1,, and Cpa5,
7 and 170 days after 50% renal mass reduction, were 78 and 64% of
normal, respectively. This decrease in renal function between days 7
and 170 post-ligation was significant (P < 0.05). Both C, and Cp,,h, 7
and 170 days after 75% renal mass reduction, were 55 and 48% of nor-
mal. respectively; however, this decrease in renal function between
days 7 and 170 post-ligation was not significant. The results show that
renal function in sheep, shortly after 50% of renal mass reduction by
arterial ligation, is much greater than that reported following unilateral
nephrectomy and that a further decrease in renal function parameters
occurs within 6 months. The mean C101 value in normal sheep was 2.46
mI/mm/kg body weight and the regression of the simultaneous Ciu and
C1,,, in normal sheep and sheep following renal mass reduction, was
C10 = 0.276 + 1.05 C1,,. The C101 value was thus 25% higher than the
corresponding Cu value and it remained significantly (P < 0.01) and
consistently higher. Thus, iothalamate can be used to measure GFR,
although a correction factor is required.
Natural killer activity and renal transplantation: Relationship to skin
cancer and inhibition by prednisolone. C. L. Keefer, R. J. Righy, R. K.
Gollogly, K. Cheung, and M. F. Robinson. Renal and Immunology
Units, Princess Alexandra Hospital, Brisbane, Australia. Natural killer
activity [NKA] has a role in immunosurveillance and was studied in re-
nal allograft recipients [RAR] to seek a correlation between NKA and
skin cancer. NKA is increased during acute rejection and inhibited by
prednisolone. The sensitivity of NK cells to inhibition by in vitro pred-
nisolone was studied in normals and transfused hemodialysis (HD) pa-
tients to determine whether a different individual response may ex-
plain the variable outcome of acute rejection treated by prednisolone.
NKA was determined with a 4-hr 5tCr release cytotoxicity assay using
K562 target cells and peripheral blood lymphocytes as effectors at a
40:1 ratio. Methylprednisolone was added to the cytotoxicity assay in
various concentrations. NKA in 123 RAR 3 months to 12 years post-
transplantation was significantly lower [6.5 9%] than in 47 normals
[39.5 17%] or in 52 HD patients [40.4 16.3%]. NKA was most
severely depressed in the 3 to 12 month period, then tended to in-
crease with time — 21% of RAR > 6 years post-transplant had NKA
within the range of the normals. Thirty-two RAR with skin cancer had
NKA [6.0 7.3%] lower than, but not significantly different from, 32
RAR [8.7 10%] without malignancy, matched for age, sex, and du-
ration of graft function. In 20 normals and 20 HD patients NKA was
inhibited by in-vitro prednisolone in a dose-dependent manner. There
was no significant difference between the percentage of inhibition with
10 g/ml prednisolone in the normals [37.2 10.5%] and the HD pa-
tients [35.4 13.8%]. Within each group the suppression by prednis-
olone appeared uniform.
Rat kidney preservation for transplantation: The effect of perfusate
composition, volume, and perfusion pressure. B. Howden, P. fabIan-
ski, D. Rae, V. C. Marshall, andJ. Tange. Monash University Depart-
ment of Surgery, Prince Henry's Hospital, Melbourne, Australia.
Clinical kidney preservation for prolonged intervals of time involves
perfusion at 4 to 8°C with a recirculating volume (500 ml) of an albu-
min-containing solution of extracellular-electrolyte composition (ALB-
ECF) at a perfusion pressure of 50 mm Hg. This study examines a new
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perfusate of 'intracellular-type': albumin-citrate (ALB-CIT) and the in-
fluence of perfusion volume (2 ml vs. 7 ml) and perfusion pressure (<
10 mm vs. 50 mm Hg). Rat kidneys are flushed with one of the test so-
lutions (ALB-ECF or ALB-CIT) and then perfused at 4°C for 24 hr
prior to transplantation into a rat of the same inbred strain. All rats re-
ceiving kidneys perfused with ALB-CIT survived. Rats receiving kid-
neys perfused with ALB-ECF survived if perfusate volume was small
(2 ml) and perfusion pressure was low (< 10 mm Hg). Serum creati-
nine values were significantly higher in all groups receiving ALB-ECF
perfused kidneys. Kidneys perfused with ALB-CIT showed minimal
morphological damage whereas 13% ALB-ECF (2 ml, low pressure),
30% ALB-ECF (7 ml, low pressure), and 50% ALB-ECF (7 ml, high
pressure) showed severe damage. Increasing perfusate volume from 2
to 7 ml had a markedly detrimental effect on the efficacy of ALB-ECF
whereas the effect on ALB-C1T was insignificant. Increasing both per-
fusate volume and perfusate pressure had a significantly detrimental ef-
fect on the efficacy of both solutions. These results suggest that clini-
cal preservation may be improved by (1) using ALB-CIT in place of
ALB-ECF, (2) reducing perfusion pressure, and (3) adjusting perfusate
volume to less than 3 ml/g kidney.
Rat kidney preservation for transplantation: The effect of 'ex vivo
perfusion.' B. Howden, P. Jablonski, V. C. Marshall, and J. Tange.
Monash University Department of Surgery, Prince Henry's Hospital,
Melbourne, Australia. A heterotopic kidney transplant model has been
developed in the rat to help overcome the necessity of delayed con-
tralateral nephrectomy. The standard orthotopic transplant involves
end-to-end anastomosis of the ureter which takes 3 to 4 days to seal,
whereas in this model the ureter is 'tunnelled' into the bladder and no
urine leakage occurs. Immediate contralateral nephrectomy is possible
unless preservation of the graft has been prolonged or inadequate. This
model has been used to study the effect of 'ex viva perfusion'. Kid-
neys that have been perfused for 48 hr in vitro under optimal condi-
tions cannot sustain life unless contralateral nephrectomy is delayed.
However, 1 hr of 'cx viva perfusion' during such a preservation pe-
riod of 48 hr improves survival and graft function. 'Ex viva perfusion'
is achieved by transplantation of the kidney into a host rat for a period
of 1 hr after 24 hr perfusion in vitro. At the end of the 'ex viva perfu-
sion' the kidney is removed, flushed and perfused for a further 23 hr in
vitro prior to transplantation into the recipient rat. Possible extensions
of this technique will be discussed.
Comparison of steroid pharmacokinetics in renal transplant patients
with and without avascular necrosis. N. Gianarakis, B. G. Charles, P.
J. Ravenscroft, J. J. B. Petrie, R. J. Rigby, and I. R. Hardie. Depart-
ment of Clinical Pharmacology and Renal Transplant Unit, Princess
Alexandra Hospital, Brisbane, Australia. The aim of the study was to
determine whether or not the development of avascular necrosis (AN)
could be correlated with the pharmacokinetics of prednisolone (PL),
cortisol (C), and prednisone (P). Twenty-four renal transplant patients
receiving corticosteroids (13 with AN) were studied. Serum concen-
trations of PL, P, and C were measured by high performance liquid
chromatography, following oral and intravenous (i.v.) administration of
the patient's usual daily dose of PL. For PL: total body clearance, area
under the curve (AUC), time to peak, peak serum concentration, bio-
logical half life (t'/2), and bioavailability did not differ significantly (P
> 0.05) between the two groups. There was also no difference be-
tween the groups (P> 0.05) in the AUC's of either C or P. Seven pairs
were matched prior to the study for body weight, age, sex, pretranspl-
ant hyperparathyroidism, total rejection treatment, and cumulative
daily PL dose. Analysis using a paired t test showed no significant
changes in any pharmacokinetic parameters apart from the predniso-
lone half life. For intravenous prednisolone I'!? in the control group
was 3.85 hr 0.54 (mean SEM) as opposed to 4.26 hr 0.55 in the
patients with AN (P < 0.01). For orally administered prednisolone ('/2
in the control group was 3.58 hr 0.66 compared with 4.00 hr 0.99
in the AN patients (P <0.05). The differences seen may have no clini-
cal significance and could simply reflect the difficulty of achieving an
adequate match. However, one patient with AN, who was severely
Cushingoid, had a PL clearance which was less than half the mean of
the group. In conclusion, it appears unlikely that pharmacokinetic vari-
ation is a major factor in the development of AN.
Pregnancy after renal transplantation. M. Abomelhu, A. A. Khader,
M. Absi, C. Metreweli, T. Sabagh, and P. J. Little. Departments of
Nephrology/ Urology, Radiology and Obstetrics, Rivadh Military Hos-
pital, Riyadh, Saudi Arabia. In the 4 years since the formation of
Riyadh Military Hospital's transplant team six patients have become
pregnant following their transplant and have been followed to deliv-
ery. Pregnancies occurred 3 to 18 months after transplantation, aver-
age 9 months. All patients had a serum creatinine below 0.19
mmoles/liter at the time of their last period. The patients were mon-
itored at weekly to fortnightly intervals throughout pregnancy by both
the transplant team and an obstetrician. Hypertension was aggres-
sively treated and bedrest was ordered whenever hypertension be-
came difficult to manage or there was apparent delay in fetal growth.
In all patients there was an improvement in renal function as mea-
sured by blood urea, serum creatinine, and creatinine clearance. In two
patients there were sequential measurements of renal size using trans-
plant ultrasound examination. It was shown that the transplant kid-
neys steadily increased in size throughout pregnancy as with normal
kidneys. All the pregnancies were completed satisfactorily, four ba-
bies being born by vaginal delivery and two by elective caesarean sec-
tion. In three patients the post-delivery renal function was better than
in the pre-pregnancy phase and in only one patient was there an ap-
parent permanent loss of renal function. In this patient serum creati-
nine rose from 0.14 mmoles/liter to 0.18 mmoles/liter at the end of preg-
nancy, having fallen to 0.1 mmoles/liter in the middle trimester. It is
suggested that this data does not support the contention that preg-
nancy should not be undertaken in the first 2 years following renal
transplantation.
Monitoring of T cell subsets in renal transplant recipients treated with
cyclosporin A (CsA). B. M. Hall, G. A. Bishop, J. Waugh, D. J. Tiller,
J. S. Horvath, G. G. Duggin, and A. G. R. Sheil. Renal Unit, Royal
Prince A(fred Hospital, Camperdown, New South Wales. Monitoring
peripheral blood T cell subsets is reported to predict whether an epi-
sode of deterioration in renal function is caused by rejection or viral
infection in recipients treated with conventional therapy. We assayed
T cell subsets three times a week in CsA treated recipients using the
monoclonal antibodies OKT3 (pan T), OKT4 (helper/inducer T), OKT8
(cytotoxic/suppressor T), OKTIO (activated T), B, (B cells). CsA
therapy did not induce changes in any subset of lymphocytes, or the
T4:8 ratio. There was no difference in the T4:8 ratio in patients with
irreversible rejection, 1.84 0.68, (4) mean SD, moderate rejection
1.42 0.25 (4), or who did not reject 1.40 0.46 (5). Rejection was
not preceded by a rise or fall in T cell subsets or the OKT4:8 ratio.
The most significant fall in T3. T4 and T8 counts was associated with
corticosteroid therapy given to treat rejection. In 16 to 18 steroid treat-
ments, the T4 fell relatively more than the T8 causing a fall in the T4:8
ratio of 0.4 (0.2— 1.0) [median (range)] which reversed after cessation
of the steroids in 13 instances. T4:T8 ratios of less than 1 were usually
associated with steroid-therapy and viral infections. TIO cells did not
increase with rejection episodes, but rose during some viral infections.
We found T cell subsets do not change with CsA therapy or with re-
jection but do change with steroid therapy and viral infections.
Factors influencing first cadaver graft survival — report from a single
center. J. J. B. Petrie, R. J. Rigby, R. W. Strong, D. Wall, and I. R.
Hardie. Renal and Transplant Units, Princess Alexandra Hospital, Bris-
bane, Australia. Between 1.1.79 and 30.10.83, 224 primary cadaver
grafts were performed. The following factors appeared to influence the
outcome. One-year actuarial graft survivals were as follows; zero
transfusions (N = 23)—25%; one and two transfusions (N =
26)—64%; three and four transfusions (N = 59)—73%; five and six
transfusions (N = 59)—79%; seven and more transfusions (N =
37)— 65%. Twenty patients with uncertain transfusion status were ex-
cluded. There would appear to be no benefit in transfusing potential
graft recipients with more than 6 U of blood. In 61 patients with zero
DR mismatches one-year graft survival was 78%, as compared to 61%
for 128 patients with one or more DR mismatches (P < 0.025 > 0.01).
Excluding nontransfused patients, however, the "split" narrowed
(77% vs. 69%; P < 0.1 > 0.05). In transfused recipients we were un-
able to show a trend. One-year actuarial graft survivals were — zero
B mismatches (N = 40) 68%; one mismatch (N = 78) 79%; two mis-
matches (N = 64) 64%. The most favored subgroup was that with 1 B
and 0 DR mismatches (N = 29); 1-year graft survival 87%. This group
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did better than 1 DR 0 B mismatches (N = 21); 1 year graft survival
69% (P < 0.05 > 0.025). Total HLA matches, total HLA mismatches
and antibody status did not appear to influence primary cadaver graft
survival.
The effect of cyclosporin A on antibody induced experimental glomeru-
lonephritis. P. U. Tipping ond S. R. Holdsworth. Deportment of Medi-
cine, Monash University, Prince Henry's Hospital, Melbourne, Aus-
tralia. The effect of cyclosporin A (CYA) on the development of ac-
tive and passive models of rat anti-glomerular basement membrane
antibody induced glomerulonephritis (anti-UBM-UN) was assessed.
Active UN was induced by preimmunizing rats with sheep globulin. Af-
ter 5 days, the injection of sheep anti-rat UBM antibody reliably pro-
duced UN with a marked cellular infiltrate (mean cells per glomerular
cross-section, c/gcs; 70.0 2.0 5EM, normal 43.6 1.1 Pc 0.01), pro-
teinuria (mean 199 36 5EM mg/24 hr, normal 5.3 0.6 P < 0.005)
and linear UBM deposition of rat IgU. Daily treatment with CYA com-
mencing 1 day prior to preimmunization prevented autologous anti-
body deposition along the UBM's and reduced the mean serum titer of
anti-sheep globulin antibody (1:3.5 treated; 1:12.0 untreated P C
0.025). Ulomerular hypercellularly was prevented (47.0 0.9 c/gcs)
and proteinuria was significantly reduced (30 9 mg/24 hr, P C 0.005).
However, treatment started after the antibody response was estab-
lished did not substantially alter subsequent antibody production, its
glomerular deposition, or the outcome of the disease. Passive anti-
UBM-UN, induced by the intravenous administration of sheep anti-rat
UBM antiserum, resulted in linear deposition of sheep IgU and rat C3
along UBM's together with glomerular hypercellularity (52.8 1.0
c/gcs) and proteinuria (105 18.2 mg/24 hr). CYA treatment had no
significant effect on this disease. Linear IgU and C3 together with
hypercellularity (50.8 0.9 c/gcs) and proteinuria (78.9 16.1 mg/24
hr) were observed to be unaffected. Thus CYA is able to block anti-
body-induced UN when given prior to induction of disease, by prevent-
ing autologous antibody production. However, it did not alter UN
when the antibody response was well established, or when glomerular
injury was passively induced.
Glomerular injury induced by a monoclonal antibody to rabbit glomer-
ular basement membrane (GBM). A. Wu, E. McGinley, R. C. Atkins,
S. R. Holdsworth, and N. M. Thomson. Deportment of Nephrology,
Prince Henry's Hospital, Melbourne, Australia. The intravenous (iv.)
injection of rabbits, rats, or guinea pigs with heterologous polyclonal
antibody to UBM results in immediate proteinuria (heterologous phase
of nephrotoxic nephritis). In the rabbit the degree of proteinuria largely
depends on the capacity of the heterologous antibody to activate com-
plement and attracts polymorphs into the glomerulus. Monoclonal anti-
bodies offer the potential to study further the mechanism(s) of injury
induced by the interaction of UBM with anti-UBM antibody. This pa-
per presents the first reported successful production of a monnclonal
antibody to rabbit UBM and examines the effect of iv. injection of the
antibody into rabbits. The monoclonal anti-rabbit UBM antibody
(P38.5) was produced by immunizing mice with particulate rabbit UBM
and using mouse splenic lymphocytes with NSI mouse myeloma cells.
The antibody was detected by the tissue staining pattern of rabbit UBM
using the immunoperoxidase antibody technique. F38.5 also reacted
when lung B.M. F38.5 was injected iv. into 12 rabbits in varying
doses. Doses in excess of 0.5 mg/kg BW resulted in heavy proteinuria
over the subsequent 24 to 48 hr the maximum proteinuria being 100
g/liter. Histology of the kidney at 24 hr showed glomerular hypercell-
ularity without a prominent infiltration by polymorphs or comple-
ment deposition. The monoclonal antibody prevented the glomerular
binding of polyclonal sheep anti-rabbit UBM antibody indicating that
the relevant UBM antigen is identical or closely related. In conclu-
sion, a monoclonal antibody to rabbit UBM has been produced and this
antibody induced heavy proteinuria by a mechanism of injury which is
independent of complement and polymorphs. This antibody will now
be used to characterize the nephritogenic UBM antigen.
Monoclonal antibody analysis of the interstitial infiltrate in glomeru-
lonephritis. D. H. Hooke and R. C. Atkins. Department of Nephrol-
ogy, Prince Henry's Hospital, Melbourne, Australia. Interstitial in-
volvement in glomerulonephritis is often not appreciated despite renal
functional impairment correlating more closely with interstitial scar-
ring than glomerular damage. The concept that similar immune and in-
flammatory mechanisms involve the interstitium as well as glomeruli
has received little attention. Therefore monoclonal markers were used
to evaluate the interstitial infiltration of leucocytes in glomerulonephri-
tis. Renal biopsy specimens from 106 patients were studied using
monoclonal markers to the following antigens: leucocyte-common
(PHM 1), monocytes (0KM I), granulocytes (FMC 10), T-lymphocytes
(9.6), T-lymphocyte subsets (OKT4, OKT8), and B-lymphocytes (Bi).
Cells were identified using a four-layer PAP technique applied to PLP
fixed 6 jim frozen sections and ten fields were counted using an eye-
piece graticule. Small numbers of leucocytes (22 6) were present in
normal renal interstitium. There was no significant increase in infil-
trating cells in biopsy specimens showing minor non-specific changes
or minimal lesion. There was however a significant increase in the in-
terstitial leucocytes (P C 0.01) in all other categories examined: focal
glomerulosclerosis (96 18); membranous nephropathy (49 9); IgA
nephropathy (105 20), diffuse mesangial proliferative lupus nephritis
(73 17), and crescentic nephritis (174 33). The interstitial leuco-
cytic infiltrate in these glomerulonephritides did not differ significantly
from that seen in six patients with an interstitial nephropathy (127
49). In the glomerulonephritides, monocytes and lymphocytes ac-
counted for 29 and 62% of the interstitial infiltrate respectively com-
pared with 31 and 31%! in normals and 17 and 69% in the interstitial
nephropathy biopsy specimens. Uranulocytes and B cells were iden-
tified only occasionally in all groups. The OKT4 /0KT84 ratio did not
differ significantly among the groups (range, 1.2 to 1.5). It is con-
cluded that interstitial mononuclear cell infiltration is an important fea-
ture of glomerulonephritis. The infiltrate is predominantly T lympho-
cytic, perhaps implicating cell-mediated immunity in the pathogenesis
of the interstitial involvement in glomerulonephritis.
The effect of corticosteroids on experimental immune complex
glomerulonephritis. P. U. Tipping and S. R. Holdsworth. Department
of Medicine, Monash University, Prince Henry's Hospital, Mel-
bourne, Australia. Deposition of immune complexes is important in the
pathogenesis of many forms of human glomerulonephritis (UN) and
vasculitis. The treatment of these diseases is often difficult and corti-
costeroids are frequently used, although their efficacy is variable and
their mechanism of action is poorly understood. A model of acute se-
rum sickness in rabbits was used to explore the effect of prednisolone
(2 mg kg' day-1) on immune complex-induced, macrophage-medi-
ated glomerular injury. The disease was induced by the intravenous in-
jection of 251 BSA (250 mg/kg) and on the day of immune elimination
(IE) (defined as 1% of 1251 BSA remaining in the circulation) resulted
in a glomerular lesion which was characterized by a diffuse prolifera-
tive endocapillary UN. Prednisolone treatment was started not more
than 48 hr prior to JE, and produced a marked attenuation of the
glomerular lesion, as well as a significant reduction of proteinuria (609
416 5EM mg/25 hr untreated, 19 6 5EM mg/24 hr treated, PC 0.05),
and of glomerular macrophage accumulation (46.3 5.7 5EM
macrophages/glomerulus (mac/glom) untreated, 10.5 7.7 5EM
mac/glom treated P C 0.005). Prednisolone treatment also resulted in
circulating monocytopenia (855 83 5EM monocytes, mm3 before
treatment, 342 59 5EM monocytes mm3 after treatment PC 0.005).
Treatment did not alter the amount of circulating immune complex; its
time oflE (11.1 0.4 5EM days untreated 11.2 0.4 5EM days treated)
or its renal deposition (2.66 0.52 5EM jig BSA/g cortex untreated,
2.36 64 jig BSA/g cortex treated). These results indicate that predn-
isolone is effective treatment for immune complex-induced glomerular
disease, where macrophages are the mediators of injury and that this
effect is not dependent on any alteration of immune complex forma-
tion or deposition.
Electron microscopic (EM) localization of glomerular components
using immunoperoxidase staining. A. E. Jackson, W. W. Hancock, R.
C. Atkins. and F. F. Ulasgow. Department of Anatomy, Monash Uni-
versity, Clayton, Victoria, Department of Nephrology, Prince Henry's
Hospital, Melbourne, Australia. Identification of cell types involved in
glomerular pathological changes, such as monocytes, lymphocytes or
proliferating intrinsic glomerular cells, has relied on morphological cri-
teria, as has identification of cell outgrowths in glomerular culture. For
conclusive identification, monoclonal antibodies have been raised
against glomerular antigens specific to epithelial, mesangial, and en-
dothelial cells, and glomerular basement membrane components, and
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characterized by light microscopic staining reactions on normal tissue.
In addition, synthesis of these antigens by cultured glomerular cells has
been studied in vitro. To establish these markers on an ultrastructural
basis, a previously unavailable EM immunoperoxidase staining tech-
nique was developed. To overcome problems of antigen sensitivity to
fixation and to the embedding process periodate-lysine-paraformalde-
hyde, fixation was followed by a pre-embedding, four-layer, peroxi-
dase-anti-peroxidase stain using specific monoclonal antibodies as the
primary marker. Ultrastructural observation showed that a monoclo-
nal antibody (PHMS) which bound specifically to podocytes in normal
kidney tissue also labeled the Type I or epithelial cells in culture, con-
firming earlier light microscopic results. Similarly prepared monoclo-
nal antibodies to mesangial cells and glomerular basement membrane
components, labeled the Type 2 or mesangial cells in culture out-
growths, as well as extracellular material produced by them. This EM
technique for identification of cell types and basement membrane in
vivo and in vitro is being applied to human biopsy material in the analy-
sis of morphological changes in glomerulonephritides.
Lithium nephrotoxicity in rabbits. R. G. Walker and P. Kincaid-
Smith. Department of Nephrology, Royal Melbourne Hospital and De-
partment of Medicine, University of Melbourne, Melbourne, Aus-
tralia. Six New Zealand White rabbits treated with LiCI 50 to 100
mmoles/kg dry wt of food (Li) and six controls (C) were observed for
up tofi months. In open renal biopsy specimens, the presence of a dis-
tinctive distal tubular lesioii (see later) was assessed. The lesion was
absent at zero months (that is, prior to any treatment but at I month
the lesion was present in six of six Li biopsy specimens and in zero of
six C biopsy specimens (x2 8.33; P < 0.005). Qualitative assess-
ment of cast formation indicated an association between the distal tu-
bular lesion and PAS positive casts and/or casts containing desquam-
ated tubular cells. A cast/renal volume cortical ration - C/V (total
number of casts/volume of renal cortex determined by a Digitizer) was
greater in Li biopsy specimens compared with C at I month (Z = 2.80;
P < 0.01). Calculated differences between values and C/V at 0 and I
month (Wilcoxon's signed rank test for ranking of differences) showed
that a marked increase in C/V had occurred in Li biopsy specimens
compared with C (P < 0.002). At 3 and 6 months, qualitative assess-
ment of interstitial fibrosis suggested an increase in Li biopsy speci-
mens compared with C, but insufficient animals have reached these
stages for adequate quantitative assessment. It is concluded that
lithium treatment in rabbits is associated with a distinctive distal tu-
bular lesion consisting of glycogen-filled granules and vacuolation of
the cytoplasm of epithelial cells of the distal nephron similar to that
seen in humans. An associated increase in cast formation with pos-
sible tubular obstruction suggests a mechanism for the development of
chronic interstitial nephropathy.
Glomerular ultrastructure and colloidal iron staining in protein over-
load nephropathy. G. B. Ryan, D. J. Davies, A. Messina, and C. M.
Thumwood. Department of Anatomy, University of Melbourne, Park-
yule, and Department of Anatomical Pathology, St. Vincent's Hospi-
tal, Fitzroy, Victoria, Australia. The development of proteinuria in rats
during systemic protein overload is a well-established model but un-
certainty remains concerning the pathogenesis of increased glomerular
permeability in such animals. In this study, male Munich-Wistar rats
were injected intraperitoneally twice daily for 4 days with 0.5 g of bo-
vine serum albumin. Proteinuria was mild during the first day, became
heavy at 2 days and reached peak levels at 3 and 4 days. Glomerular
ultrastructure was examined in these animals following vascular perfu-
sion fixation or in situ drip-fixation of superficial glomeruli in vivo.
Podocytic epithelial cells showed extensive replacement of foot proc-
esses by flattened, continuous expanses of epithelial cytoplasm, detect-
able at 1 day and considerably more widespread at 2 to 4 days. Areas
of epithelial loss, leaving segments of externally bare glomerular base-
ment membrane, were present at 2 to 4 days following both methods
of fixation. As in aminonucleoside nephrosis, it appears likely that such
areas of bare basement membrane are important sites of leakage of
plasma protein into Bowman's capsular space. In glomeruli examined
following drip-fixation in vivo, the ultrastructural colloidal iron tech-
nique revealed no loss of staining for negatively charged groups on
podocytic epithelial surfaces or elsewhere in the glomerular capillary
wall at any stage. Thus, the reduction in colloidal iron staining re-
ported in such glomeruli on the basis of light microscopic studies re-
sults from a decrease in podocytic surface area due to cytoplasmic
spreading rather than a loss of intrinsic polyanion from the filtering por-
tion of the glomerular capillary wall. These findings question the pri-
mary role of loss of intrinsic negative groups from the glomerulus in
the pathogenesis of proteinuria in protein overload nephropathy.
Antibody specificity of mesangial IgA deposits in alcoholic liver dis-
ease. J. D. Lomax-Smith, R. H. C. Harries, A. E. Seymour, and A. J.
Woodroffe. The Renal Unit, Royal Adelaide Hospital, Adelaide, Aus-
tralia. Mesangial igA deposits are found at autopsy in 50% of subjects
with alcoholic liver disease (ALD). This may be related to an ab-
normal uptake of intestinal antigens, decreased clearance of immune
complexes and IgA polymers or an increased production of IgA to in-
testinal antigens and Mallory's hyaline. Kidneys were obtained at post-
mortem from nine subjects with ALD and mesangial IgA deposits.
Washed glomerular suspensions were eluted with citrate buffer pH 3.2
and the concentrated eluates tested for antibody reactivity to bovine
serum albumin (BSA) (RIA), Escherichia coli (ELISA), and Mallory
bodies (MB) (indirect IF). The results are shown in the table.
Eluate
Antibody specificity
MB E. coli BSA
1 + + —
2 -t- — —
3 + + —
4 + — —
5 — + —
6 + — +
7 + — —
8 + -I- —
9 — + +
Normal kidney — — —
These findings indicate that the mesangial IgA deposits associated with
ALD have multiple antibody specificities. To date, only one of the cor-
responding antigens (MB) has been identified in the mesangial depos-
its.
IgA nephropathy: Clinicopathological correlations. D. C. H. Harris,
L. S. Ibels, C. Lauer, J. V. Wells, and P. Kirwin. The Royal North
Shore Hospital of Sydney, Sydney, Australia. Clinical and pathologi-
cal prediction of outcome in IgA nephropathy is controversial, and the
significance of macroscopic hematuria is debated. Of 47 consecutive
patients with IgA nephropathy, 33 were followed for more than 1 year
(mean, 34 months). Abnormal glomerular function (GFR < 1.0 ml/sec)
occurred in 33% and hypertension in 54%; both occurred early. Eight
patients had a complete remission and three progressed to endstage re-
nal failure. Clinical features at presentation which predicted a poor out-
come included proteinuria (P < 0.05), especially when heavy (P <
0.005), the absence of macroscopic hematuria (P < 0.01) and age was
greater than 35 years (P approximates 0.05). Serology failed to predict
prognosis but a raised serum IgA level was associated with a history
of antecedent pharyngitis (NS). GFR of less than 1.0 mI/sec was as-
sociated with focal sclerosis (P < 0.001), global sclerosis (P < 0.025),
tubular hypertrophy (P < 0.0005). interstitial fibrosis (P < 0.05), and
inflammation (P < 0.0005), vascular changes (P < 0.0005) and "healed
glomerular inflammation" (P < 0.025). Electronmicroscopy (EM) was
performed in 26 patients; features which predicted a poor outcome in-
cluded electrondense deposits on glomerular basement membrane
(GBM, P < 0.01), especially when subepithelial (P < 0.01), and in ar-
terial walls (P < 0.01), GBM splitting (P < 0.005) and thinning (P <
0.005), and interstitial infiltrate (P < 0.005). Immunofluorescence mi-
croscopy (IF), although diagnostic, was not useful in prognostication.
Macroscopic hernaturia (in 40%) was associated with a history of an-
tecedent pharyngitis (NS), normal renal function (P < 0.01) and blood
pressure (P < 0.01), normal or near normal light microscopy (NS), but
not crescents or "active glomerular inflammation," and fibrinogen on
IF (P < 0.05). In this series, EM proved more useful than light micros-
copy in predicting outcome, and macroscopic hematuria was associ-
ated with a benign prognosis.
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Patterns of lead excretion in patients with gout and chronic renal fail-
ure—a combined German and Australian study. P. Craswell, P. Boyle,
E. Low, D. Behringer, F. Ritz, and N. Stoeppler. Royal Brisbane Hos-
pital, Queensland, Australia, and Klinikuin der Universität Heid-
elberg and Institut für Chemie, JOlich, Federal Republic of Germany.
The 6-day calcium EDTA lead excretion test was performed in Ger-
man (Ger) and Australian (Aus) patients with renal failure (some of
whom had gout) to determine if the pattern of results differed between
the two countries and if those with gout excreted more lead than those
without. A positive test is less than 2.9 moles of excess lead. Six GER
and five AUS (four of each had gout) had industrial lead exposure.
Twenty-seven AUS and no GER had childhood exposure to lead (14
with and 13 without gout).
Ger. gout Ger. no gout Aus. gout Aus. no gout
20 42 32
45 62 57
0.53 0.32 0.5 0.32 0.53 0.34 0.51 0.32
The lead date being non-parametric was log, transformed and ana-
lyzed using unpaired t test and SPSS one- and two-way factorial analy-
sis of variance. The mean excess lead excreted and the proportion of
positive tests were significantly greater in the Aus gout and no gout
groups. Nationality, gout, and lead exposure all had significant influ-
ences on lead excretion. However, within the Australian population (N
= 72) neither gout nor lead exposure were significant influences in con-
trast to the German data. Five Australian controls were available who
all had normal renal function and did not have a history of past expo-
sure to lead in childhood or from industry. Their mean lead excretion
of 1.05 0.58 was significantly higher than that of 19 German con-
trols (0.45 0.51; t 2.29, P < 0.05). These results suggest that citi-
zens living in Queensland have a greater exposure to lead than those
in Germany possibly through childhood exposure to lead paint.
A controlled trial of levamisole in frequently relapsing minimal change
disease. M. G. Kirubakaran, G. K. Jacob, A. Date, andJ. C. M. Shas-
try. Christian Medical College and Hospital, Vellor, South India. Mini-
mal change disease (MCD) is postulated to be due to T-lymphocyte
dysfunction. Levamisole (L) has been effectively used in several dis-
orders with T-cell dysfunction and it probably acts by restoring nor-
mal T-cell activity. Random trials have shown L to be effective in MCD
also. A controlled trial was undertaken to assess the value of L in re-
ducing the frequency of relapses in steroid responsive, frequently re-
lapsing MCD. Twenty-four patients with biopsy proven MCD having
three or more relapses per year were randomly allocated to two equal
control (CG) and trial (TG) groups at the time of a relapse. Both groups
were treated with prednisolone 2 mg/kg on alternate days until remis-
sion was induced, followed by tapering off of the dose in 8 to 12 weeks.
The TG then received L at 3 to 5 mg/kg on alternate days for 12 weeks.
All patients were followed for 18 months. Further relapses were treated
with prednisolone only. Both groups were comparable in age, sex, age
at onset, duration, and relapse rate of MCD. Before the trial, CG and
TG had a yearly mean of 3.6 apd 3.8 relapses, respectively. During the
trial, CG had a mean of 3.1 while TG had a mean of 1.1 relapses. In
the TG, seven patients had no relapses at all, two relapsed after 12
months, and three had frequent relapses. No side effects of L were ob-
served in any. L may be a valuable adjuvant in the treatment of fre-
quently relapsing MCD.
Cellulose phosphate or chlorothiazide in childhood idiopathic hyper-
calciuria. J. R. Burke andD. Cowley. Mater Misericordiae Children's,
Royal Children's and Princess Alexandra Hospitals, Brisbane, Aus-
tralia. Idiopathic hypercalciuria, the most frequently identified meta-
bolic cause of nephrolithiasis in adults may present as hematuria with
or without demonstrable calculi in children. Eight Queensland chil-
dren, I to 12 years of age are reviewed (experience 1978 to 1983) with
normal diet 24-hr calcium excretion greater than 0.10 mmoles/kg/day
(4 mg/kg/day). None had infection, distal RTA, hyperparathyroidism,
or vitamin D ingestion and all were ambulant with normal serum bio-
chemistry. Four presented with abdominal pain, three with painless he-
maturia, and one with dysuria. Six had identifiable stones. Four stones
contained calcium, phosphate, and oxalate. Five stone-forming rela-
tives had hypercalciuria. A calcium loading test identified the hyper-
absorptive form of hypercalciuria in six of seven children. Serum parat-
hormone was in the low normal range in all patients (< 40 pmoles/liter)
and phosphate excretion index was not elevated. Chlorothiazide (10 to
30 mg/kg) reduced urinary calcium into the normal range in only one
of six patients. Urine calcium was reduced into the normal range in all
four children given cellulose phosphate. Hyperabsorptive hyper-
calciuria is most likely caused by a primary increase in gut calcium ab-
sorption and not a primary phosphate leak from the kidney. Idiopathic
hypercalciuria should be considered in children with recurrent hema-
tuna with or without pain, especially if there is a family history of
stones. Cellulose phosphate is indicated in children with recurrent
stone formation and in whom calcium loading test identifies the hyper-
absorption form of hypercalciuria.
Microbiological investigations on women with abacterial cystitis. R. R.
4 4.1 Bailey, B. A. Peddie, J. Tait, G. Russel, V. A. Bishop, and E. P.
15 Arnold. Departments of Nephrology and Urology, Christchurch Hos-
pital, Christchurch, New Zealand. The etiology of abacterial cystitis
(urethral syndrome) is unknown. This study was undertaken to inves-
tigate a possible cause of this common condition. Thirty-one women
(age range, 17 to 77 years; mean, 38 years) with bacterial cystitis were
studied. The mean duration of symptomatic episodes was 5 years.
Eight control subjects (mean age, 33 years) were also studied. De-
tailed clinical histories were recorded. Suprapublic bladder aspirates
and voided urine specimens were cultured for aerobic and anerobic
bacteria, cell wall-deficient bacteria, fungi and some for ureaplasma ur-
ealyticum. Urethral and cervical swabs were cultured for fungi, ChIa-
mydia trachomatis, and Herpes simplex. Cystoscopy was done and trig-
onal biopsy specimens taken. No consistent clinical features were ap-
parent from the patients' histories. Four patients had infected bladder
urine; 2 cell wall-deficient Streptococcus sp; I slow-growing Strepto-
coccus sp isolated after anerobic incubation for 5 days and I Lac-
tobacillus sp and U. urealyticum. The former two were isolated from
patients who had recently received antimicrobial therapy. Lactobacil-
lus sp was cultured from the bladder urine of one control subject. All
voided urine samples from both patients and control subjects grew
Lactobacillus sp. Yeasts were isolated from urethral and vaginal swabs
of three patients and one control subject. C. trachomatis and H. sim-
plex were isolated from the urethra and vagina of one patient. Four of
24 patients and neither of two controls had U. urealyticum in urethral
swabs and voided urine specimens. No gonococci were isolated. No
consistent microbiologic cause was found for the syndrome of abac-
terial cystitis which is almost certainly multifactorial in etiology.
Renal disease in the South Australian aboriginal population. D. J.
Pugsley, B. Grime, and A. Esterman. Renal Unit, Queen Elizabeth
Hospital, Adelaide and Aboriginal Health Organisation, South Aus-
tralian Health Commission, Adelaide, Australia. The prevalence of re-
nal disease, diabetes mellitus, and hypertension was studied in 1,078
aboriginal subjects (females 54.5%; males 45.5%) — the population of
eight suburban, rural, and tribal settlements. All subjects had their
urine examined by dipstix (Ames). The finding of I + or more for
blood, glucose, or protein led to a repeat test. If an abnormal result was
confirmed, renal disease (RD) was considered to be present. The BP
was measured by a trained nurse, who also collected data relating to
tribe, sex, age, weight, height, skinfold thickness, and upper arm cir-
cumference. RD, thus defined, was observed in 140 (13%) of patients
(females 15.5%; males 10%). Further analyses excluding subjects with
hematuria (H) unaccompanied by proteinuria (P), and cases of H
thought to be of lower urinary tract origin, also showed an excess
prevalence among females. RD was positively correlated with both age
and body mass index (wgt/hgt2). Further analyses are being under-
taken to show the relative dependency of RD on these variables. The
prevalence of RD was significantly greater in tribal than rural (P
7
53
No.
Age
Plasma
creat,
mmoles/
liter
Lead
excess,
smoles 2.4 1.4 1.03 0.84 5.8 6.2
Pos. test 2 0 29
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0.025) or suburban areas (P = < 0.05). The BP of subjects with RD
was significantly greater than those without urinary, abnormality (P =
< 0.001). Twelve patients with impaired renal function (serum creati-
nine > 120 zmolesIliter or blood urea > 8 rmoles/liter) were detected
from blood tests carried out on subjects with urinary abnormalities.
Half of the patients with diabetes had P. Although there are no other
similar studies, it is widely believed that P and/or H would not be en-
countered in more than 1 to 2% of the population. These data suggest
therefore that there is a very high prevalence rate of RD in the abo-
riginal community. The observed frequency of renal failure is at least
ten times that anticipated, and together with the finding of P in 50% of
the patients with diabetes carries disturbing implications that merit fur-
ther definitive studies.
Rhabdomyolysis acute renal failure (RMARF). M. A. B. Thomas and
L. S. Ibels. Royal North Shore Hospital, St. Leonards, New South
Wales. The prevalence, clinical, biochemical, and management fea-
tures, and prognosis of II patients with RMARF are presented, includ-
ing one with a previously undescribed etiology, lower limb streptococ-
cal cellulitis. Over a 20-month period, 127 patients presented with
acute renal failure, a prevalence of RMARF of 8.6%. These patients
(ten male, one female) were aged 15 to 72 (mean 38) years. Precipi-
tants of RM were infection in two, trauma in two, overdose coma in
two, ischemia in two and alcohol, exercise and electrical shock in each
one patient. Two of these had coexistent alcohol abuse and hypokal-
emia. Eight had apparent muscle damage while three had myalgia and
weakness alone. The peak CPK was 1,430 to 842,000 (mean 141,675)
piliter, myoglobin > 800 tgI1iter, Cr 0.03 to 0.34 (mean 0.22)
mmoleslliter/day, P04 0.95 to 3.55 (mean 2.39) mmoles/liter, K 3.4 to
6.9 (mean 5.5) mmoles/liter, UA 0.57 to 1.4 (mean 0.7) mmoles/liter,
urea 7.5 to 49.5 (mean 25.6) mmoles/liter, Cr 0.17 to 1.39 (mean 0.62)
mmoles/liter, trough Ca 1.3 to 2.35 (mean 1.76) mmoles/liter and peak
recovery Ca 2.1 to 3.6 (mean 2.59) mmoleslliter. Three had false nega-
tive tests for urinary myoglobin. Urine was pink or brown in eight he-
matest positive and with pigmented granular casts in all. Fasciotomy
was necessary in four and amputation in three. Diuresis and urinary
alkalinization was tried in most. Oliguria for 6 to 81 (mean 24) days oc-
curred in seven. Complications induced hypercalcemia in two, infec-
tion in three, nerve damage in three and death in one. Follow-up for
0.5 to 16 (mean 5.3) months has shown normal renal function in all but
one patient (Cr 0.25 mmoleslliter). RMARF accounts for nearly 10%
of patients with acute renal failure, may not present with clinically ap-
parent RM, may be associated with falsely negative urinary myoglobin
estimations, has characteristic biochemistry, and has a good progno-
sis.
Wegener granulomatosis with renal involvement: Is it ever cured? N.
M. Thomson, D. Gee, C. Wood, S. R. Holdsworth, and R. C. Atkins.
Department of Nephrology, Prince henry's Hospital, Melbourne, Aus-
tralia. Since 1972, eight patients with Wegener granulomatosis (WG)
with renal involvement have been successfully treated with im-
munosuppression but seven have undergone relapse after cessation of
immunosuppression. This high rate of relapse, which contrasts to that
of other investigators (4%), led us to review the clinical features of
these patients, immunosuppressive regime and patterns of remission
and relapse. All patients (mean age, 45.6 years: 22 to 74) had clinical,
radiological, or histological evidence of WG involving the upper and
lower respiratory tract and seven of eight had other systemic symp-
toms. All patients had renal impairment: mean serum creatinine 606
/Lmoleslliter (range, 130 to 1200). Renal biopsy specimens showed fo-
cal or diffuse necrotizing crescentic glomerulonephritis: mean% age of
crescents 78% (50 to 100%). Six patients were treated with a combi-
nation of prednisolone and cyclophosphamide (plus plasma exchange
in one of six) and two were treated with prednisolone alone. Complete
resolution of non-renal manifestations were seen in seven of eight pa-
tients with partial resolution in one of eight (on steroids alone). Renal
function improved in seven of eight patients; the mean serum creati-
nine fell to 170 jtmoles/liter (ran8e, 120 to 280), but failed to improve
in one patient anuric at presentation, who was later transplanted and
has remained in remission on azathioprine. Despite continuation of im-
munosuppression for at least 12 months after remission of WG in the
remaining seven patients, all have subsequently developed relapse of
the disease within 3 months to 5 years (mean, 1.5 years). Despite re-
introduction of immunosuppression in six patients, five of six devel-
oped irreversible renal failure although non-renal manifestations were
controlled. Complications of immunosuppression included pneumonia
(3/8), SCC (118), and perforated colon (1/8). it is concluded that re-
lapse of WG after cessation of prolonged immunosuppression is com-
mon in patients with severe renal involvement and the effect is often
catastrophic. Much longer or even permanent immunosuppression may
be warranted.
Cellular electrolyte transport in Bartter syndrome. E. D. M. Gallery,
G. Koumantakis, C. Bean, R. Grigg, and A. Z. Gyory. Departments
of Renal Medicine and Medicine, Royal North Shore Hospital and
Sydney University, Sydney, Australia. Bartter syndrome is character-
ized by hyperreninemic hyperaldosteronism, urinary sodium, and po-
tassium wasting and other variable abnormalities in renal tubular func
tion. It is uncertain whether the primary abnormality is of renin secre-
tion or of tubular cellular electrolyte handling. The disorder has been
described in several members of families, and studies of normal and ab-
normal family members may elucidate the underlying abnormalities.
Na/K transport characteristics in red blood cells were studied from
four members of a family, three of whom were affected by Bartter syn-
drome and compared to those of 14 normal males. Results are in the
table:
Intracellular Na
Intracellular K
Max. net Na efflux rate
Max. net K influx rate
Rb86 uptake:
Net
Ouab. sens.
Furos. sens.
Ouab. & Furos. sens.
Normal
(N = 14)
Family members(N=4) P
Intracellular Na 12.2 0.17 NS
Intracellular K 89.0 1,5 NS
Max. net Na' efliux rate 3.6 0.40 <0.05
Max. net K influx rate 2.0 0.17 <0.01
Rb86 uptake:
Net 315 6.4 <0.01
Ouab. sens. 216 2.5 <0.05
Furos. sens. 109 27.0 NS
Ouab. & Furos. sens. 27 2.0 <0.001
These results show reduced maximum net K influx in the face of low
Ki, and increased net and ouabain sensitive Rb influx. The discrep-
ancy can be explained by the finding of increased ouabain and furo-
semide insensitive (? passive) Rb influx, which could also represent in-
creased effiux; these bidirectional movements obscure the maximum
measurements. It is possible therefore that the primary abnormality is
increased passive leak across cell membranes, leading to a compen-
satory increase in active transport, and maintenance of normal intra-
cellular electrolytes. The abnormality is not due to aldosterone, as the
unaffected family member (the youngest) had the same findings de-
spite the lack of other stigmata of Bartter syndrome, including normal
renin and aldosterone levels.
A clinical study of dense deposit disease (DDD). R. G. Fa,sset, E.
Viguier, A. d'Apice, J. P. Dowling, and P. Kincaid-S,nith. Depart-
ment of Nephrology, Royal Melbourne Hospital, Parkville, Victoria,
Australia. Twenty-three patients with DDD were followed for a mean
of 8.7 years (range, 0.5 to 20 years), the female:malc ratio was 2.6:1
and the median age of onset was 14.1 years (range, 4 to 38). The most
(mmoles/liter cells)
(mmoles/liter cells)
(mmoles/liter cells/hr)
(mmoles/liter cells/hr)
(nmoles/109 cells/hr)
(nmoles/109 cells/hr)
(nmoles/l09 cells/hr)
(nmoles/109 cells/br)
12.3 0.05
92.0 0.8
4.4 0.14
2.4 0.08
253 10.0
183 7.2
80 8.6
13 1.6
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common presentation was macroscopic hematuria (H) 24 to 48 hr after
a sore throat (7), incidental H and/or proteinuria (P) (5) or in associa-
tion with pregnancy (4). At the onset loin pain occurred in two, six had
hypertension (HT), one had impaired renal function and 11 had the ne-
phrotic syndrome (NS). Patients fell into two groups: Gi with progres-
sive impairment of renal function (11) and G2 who showed no progres-
sion (II). Recurrent macroscopic H and persistent microscopic H were
more common in GI. Overall H, P, and pyuria were greater in Gi (see
table).
tion of 6 Keto PGF1a and decreased serum thromboxane and plasma
renin activity. Indo was associated with a significant fall in plasma no-
radrenaline by day 7 and blunting of the noradrenaline response to or-
thostasis. No change was seen with sulindac (or placebo). The effect
of Indo on blood pressure and PRA in hypertensive subjects is con-
sistent with PG synthesis inhibition. The previously reported absence
of an effect of sulindac may be due to inadequate cyclo-oxygenase in-
hibition rather than a postulated differential effect on renal and platelet
cyclo-oxygenase.
Mean urinary RBC/ml 268,391 15,475 <0.005
Mean urinary protein g/liter 4.78 1.44 <0.001
Mean urinary WBC/ml 74,578 6,167 <0.001
Ten of 11 subjects in GI had the NS at onset and HT was more com-
mon and severe in Gl . Six subjects had partial lipodystrophy. C3 nef
was present in six of six subjects tested. C4 was normal in all. All GI
subjects had reduced C3 levels at Onset. Eight subjects commenced
dialysis at a mean of 17.1 years after Onset (range, 3.4 to 28.6 years).
The 50% survival occurred between the 21st and 22nd years. Five sub-
jects had renal transplants, three failed, all had evidence of recurrent
DDD but in only one did it contribute to graft loss. Fourteen pregnan-
cies occurred in seven females and none had any deterioration of renal
function and all pregnancies were successful. Fifteen subjects had 28
courses of varying therapy (anti-coagulants, antiplatelets, immunosup-
pressants) and only two subjects had clearcut responses.
Abdominal ultrasound in pregnancy: An aid in the early diagnosis and
treatment of structural urological abnormalities. S. G. Copper, R. H.
Farnsworth, A. R. Rosenberg, and W. J. Garrett. Departments of
Nephrology, Urology and Ultrasonography, The Prince of Wales
Children's Hospital, The Prince Henry Hospital and The Royal Hos-
pital for Women, New South Wales. Ten children are described in
whom routine antenatal abdominal ultrasound revealed structural uro-
logical abnormalities. Fetal age at diagnosis and delivery ranged be-
tween 25 to 39 and 28 to 40 weeks, respectively. Birth weights were
appropriate for gestational age. The lesions were confirmed post-
natally by ultrasound and appropriate radiological studies. The cases
comprised bilateral pelvi-ureteric junction (PUJ) obstruction (4), uni-
lateral PUJ obstruction (2), obstructive megaureter (2), megacystic-
megaureter syndrome (1), and bilateral duplex system with obstructive
ureterocoele (1). Surgery was performed on day 1 in four children, and
within 20 days in the remainder. Hospital stay ranged between 14 to
39 days. In five of the ten children no abnormality could be found on
clinical examination in spite of awareness of the ultrasound findings.
Congenital obstructive anomalies of the urinary tract, if not diagnosed
and treated early, may result in hypertension and/or chronic renal fail-
ure. While routine ultrasonic examination in pregnancy would uncover
more such cases, its cost effectiveness is unresolved.
A comparison of the effects of sulindac and indomethacin on renal
function and blood pressure in humans. 1. B. Puddey, L. J. Beilin, and
R. Vandongen. Department of Medicine, University of Western Aus-
tralia, Perth, Western Australia. The newer NSAID, sulindac, ap-
pears in preliminary studies to be devoid of an influence on both renal
prostaglandin excretion and PRA. Because of the potential clinical im-
portance of this property we have compared the effects of sulindac and
indomethacin (Tndo) on renal function and blood pressure in 26 sub-
jects with treated essential hypertension. Subjects were randomly as-
signed to one of three treatment groups — Indo 25mg tds (N 9), sulin-
dac 200 mg bd (N = 9), or placebo (N = 8) and assessed at day 0, 3,
7, and 28 of therapy. Supine SBP but not DBP, significantly increased
by day 7 with Indo (repeated measures ANOVA, F 6.83, P <0.01).
No significant change was seen with sulindac or placebo. (Indo 142.9
5.0/86.8 1.7 to 153.9 6.1/90.4 3.2, sulindac 138.4 4.1/79.8
2.9 to 128.6 4.9/75.3 2.7, placebo 125,7 3.8/84.9 2.7 to
127.0 7.0/82.1 3.2 mm Hg). This pressor effect was still evident
at day 28 and associated with a significant increase in weight. Plasma
urea and Cr, Cr clearance, and GFR were unaltered by placebo or su-
lindac, while Indo caused a significant increase in urea but no other
change in renal function. Indo but not sulindac blunted urinary excre-
p Antibodies to Tamm-Horsfall urinary glycoprotein in patients with uri-
nary tract infection, reflux nephropathy, urinary tract obstruction, and
paraplegia. K. L. Lynn, R. R. Bailey, A. Groufsky, J. S. Hunt, A. R.
Bean, and A. R. McGiven. Departments of Nephrology and Pathol-
ogy, Christchurch Hospital and Spinal Injuries Unit, Burwood HOs-
pital, Christchurch, New Zealand. It has been suggested that autoanti-
bodies to Tamm-Horsfall urinary glycoprotein (anti-TH) are relevant to
renal infection, obstruction, and scarring. Anti-TH antibodies were
measured by ELISA in 16 patients (three men) with acute pyelonephri-
tis (APN) and eight women with cystitis at intervals up to 150 days fol-
lowing diagnosis, and in 39 patients (nine men) with reflux nephrop-
athy (RN), 15 men with acute urinary retention and 34 patients (three
women) with spinal injuries. The change in anti-TH titer in patients
with APN was highly variable. The mean titer at presentation was sig-
nificantly greater than normal (P < 0.01) but not different from that in
cystitis (P = 0.1). There was, however, a significant difference in vari-
ance between the two groups (F = 7.6, P < 0.01). Peak anti-TH titer
did not distinguish APN from cystitis. Fifteen of 34 patients (44%) with
paraplegia had raised anti-TH titers, but anti-TH titer did not correlate
with urinary tract infectjon, duration of paraplegia or renal function.
Anti-TH titers were normal in RN and acute urinary retention and not
related to renal function or morphology. No evidence involving TH in
the pathogenesis of RN has been demonstrated. Further long-term
studies are required to evaluate the significance of raised anti-TH ti-
ters in patients with urinary tract infection and paraplegia.
Comparison of netilmicin with cefoperazone for the treatment of se-
vere or complicated urinary tract infections. R, R. Bailey, B. A. Ped-
die, K. L. Lynn, C. P. Swainson, and E. Blake. Department of
Nephrology, Christchurch Hospital, Christchurch, New Zealand. The
search continues for more effective and safer antimicrobial agents for
the treatment of patients with severe or complicated urinary tract in-
fections (UTIs). Many investigators consider that the aminoglycosides
are the antibiotics of choice for the treatment of severe gram-negative
infections, while others prefer the newer beta-lactam drugs. We have
reported our early experience with netilmicin and cefoperazone for the
treatment of UTIs. However, these studies were open and non-com-
parative. We now report a randomized trial comparing the efficacy and
safety of netilmicin and cefoperazone for the treatment of severe or
complicated UTIs. Thirty-one patients completed the study. Fifteen of
16 patients treated with netilmicin (2 mg/kg loading dose; maintenance
doses adjusted according to creatinine clearance) and 9 of 15 treated
with cefoperazone (1 to 2 g 12—hourly) were cured. All were treated
for at least 5 days. This difference in cure rate was statistically signif-
icant (Fisher's Exact Probability test, 2 tailed, P = 0.037). Netilmicin
failed to eradicate a chronic Pseudomonas aeruginosa infection from
an elderly woman with a grossly abnormal urinary tract. Of those
treated with cefoperazone, two were reinfected with Streptococcus
faecalis, a paraplegic man with renal calculi had only one of two patho-
gens eliminated, and three patients did not have their original orga-
nism eradicated. No serious side effects or toxicity occurred with ei-
ther drug. This study confirms our uncontrolled observations that the
aminoglycosides are more effective than the beta lactam antibiotics for
the treatment of severe or complicated UTIs.
Single-dose netilmicin in urinary infection. B. F. Murphy and K. F.
Fairley. Royal Melbourne Hospital, Melbourne, Australia. Single-dose
therapy is an effective and increasingly popular treatment for urinary
infection. Parenteral therapy has the advantage of assured patient com-
pliance yet there is limited data on the efficacy of drugs used in this
way. Netilmicin is a semisynthetic aminoglycoside derived from gen-
tamicin CIa. This study examines the efficacy of single-dose netilmicin
in the management of uncomplicated urinary infection. The study was
Group I Group 2
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conducted simultaneously at three institutions (Royal Melbourne Hos-
pital, Queen Elizabeth Hospital, South Australia and Christchurch
Hospital. Seventy-nine patients (75 women. 4 men, age 17—89) were
studied. Sixty-one had symptomatic cystitis and 18 asymptomatic bac-
teriuria. Patients were given a single dose of 150 mg netilmicin intra-
muscularly and urine cultures were repeated 7 or 8 days later. Clinical
and bacteriological cures were effected in 52 of the 61 patients present-
ing with symptomatic infection. Fifteen of the 18 asymptomatic pa-
tients were bacteriologically cured resulting in an overall cure rate of
85%. No side effects from the netilmicin injection were reported. We
conclude that netilmicin is well-tolerated and of comparable efficacy to
other drugs when used in single dose.
Single.dose therapy of uncomplicated urinary tract infections. R. R.
Bailey, B. A. Peddie, E. Blake, and V. Bishop. Department of Nephrol-
ogy, Christchurch Hospital, Christchurch, New Zealand. Uncompli-
cated UTIs are treated with large doses of antimicrobial agents pre-
scribed for longer than necessary. There is no evidence that a long
course of treatment is more effective than a short one. We have pre-
viously reported that a single 3-g dose of amoxycillin was comparable
to a 5-day course of amoxycillin, and a 1.92- or 2.88-g dose of cotri-
moxazole (CTM) was as effective as 5 days of CTM. We have com-
pleted two further trials: (1) Fifty non-pregnant women with bacterial
cystitis or covert bacteriuria were randomly allocated to treatment with
either a single 150-mg i.m. dose of netilmicin or 5 days of CTM. Eight
patients were excluded because they had abacterial cystitis. Twenty-
one of 22 were cured with netilmicin and all 20 with CTM. No patient
treated with netilmicin developed any side effects or obvious toxicity.
Following CTM one woman developed a severe skin rash and another
nausea. Netimicin is another drug which is highly effective when used
in a single dose for the treatment of uncomplicated UTIs. (2) Forty-
four women with covert bacteriuria of pregnancy during the second tri-
mester were randomly allocated to either 1.92 g of CTM or 5 days of
CTM. Twenty-one of 24 women were cured with a single dose and all
20 treated with a 5-day course. There were no side effects of detrimen-
tal effects on the pregnancy. The advantages of single dose therapy for
uncomplicated UTIs are that it is simple, effective, cheap, well-toler-
ated, preferred by patients, assured compliancy, fewer side effects,
less risk of producing resistant gut organisms or hazard to the fetus,
and possibly an indicator of those with urinary tract abnormalities.
Focal necrotizing glomerulonephritis — A teaching hospital's experi-
ence. T. Furlong, M. A. B. Thomas, and L. S. Ibels. Royal North
Shore Hospital, St. Leonards, New South Wales. This study reports
the prevalence, clinical features, histology, and response to treatment
of patients with focal necrotizing glomerulonephritis (GN) at North
Shore Hospital over a 6-year period. Eighteen patients had focal nec-
rotizing GN, representing 5% of 374 patients with GN (3% of 240 pri-
mary GN, 7% of 134 secondary GN). These 18 patients (10 male, 8 fe-
male) were aged 5 to 74 years (mean 48). The majority presented with
constitutional symptoms, were normotensive, and had both hematuria
and proteinuria (> 3 g/day in 4). Associated illnesses included
Goodpastures syndrome in three patients, systemic vasculitis in four,
Wegener granulomatosis in two and infective endocarditis in one. Ad-
mission creatinine values ranged from 0.11 to 2.03 mmoles/liter. The
course was rapidly progressive in nine patients. Rena! biopsy showed
predominant focal glomerular necrosis with variable crescent forma-
tion and interstitial inflammation. Sixteen patients received aggressive
corticosteroid and immunosuppressive therapy combined with plasma
exchange in eight and anticoagulation in three, with improvement in re-
nal function in all but one patient, who had an initial creatinine of 2.03
mmoles/liter and who died from herpes encephalitis. Two other deaths
were due to a cerebral thrombosis and septicemia. Of the two un-
treated patients, one was commenced on maintenance dialysis, being
assessed as having irreversible renal failure on biopsy and the patient
with endocarditis regained renal function with valve replacement and
antibiotic therapy. Focal necrotizing GN is not an uncommon form of
GN, often has a fulminant clinical course but responds well to aggres-
sive treatment if initiated early.
Renin.angiotensin-aldosterone system in nephrotic syndrome. T. G.
Hammond, J. A. Whitworth, D. Saines, R. Thatcher, J. Andrews, and
P. Kincaid-Smith. The Royal Melbourne Hospital, Victoria, Australia.
Previous studies on the renin-angiotensin-aldosterone system and fluid
volumes in patients with nephrotic syndrome have not considered the
nature of the underlying renal lesion. We compared plasma renin con-
centration (PRC), plasma aldosterone (PA), and plasma volume in
three groups of patients: five nephrotic patients with minimal change
disease on renal biopsy, seven nephrotic patients with other renal his-
topathology, and a control group of eight patients investigated for gb-
merulonephritis with no past or present nephrosis. PRC and PA were
significantly greater in nephrotic patients with minimal change disease
other than renal histopathology (supine PRC 42 7 iilU/ml, com-
pared with 14 4, P < 0.01; ambulant PRC 56 7 dU/ml, com-
pared with 29 10, P < 0.05; supine PA 158 55 pg/mI compared
with 53 13, P < 0.05; and ambulant PA 167 57 pg/mI compared
with 29 10, (P < 0.05). Plasma volume was similar in all three
groups, contrary to predictions from the Starling capillary fluid ex-
change hypothesis. Nephrosis maybe characterized by different patho-
physiological groups according to the underlying renal histopathology.
High plasma renin and aldosterone levels may act as markers for mini-
mal change disease, and hence steroid responsiveness in patients with
nephrotic syndrome.
Enalapril in treatment of hypertension. B. F. Murphy, J. A. Whit-
worth, and P. 5. Kincaid-Smith. The Royal Melbourne Hospital, Mel-
bourne, Australia. Enalapril is a newly developed angiotensin convert-
ing enzyme inhibitor structurally dissimilar to captopril. We have
treated 14 hypertensive patients with enalapril, 8 patients with renovas-
cular hypertension (group 1), and 6 patients with severe hypertension
who were intolerant of captopril (group 2). Enalapril was introduced
at 2.5 mg increasing to a maximum of 20 mg b.d. If BP remained un-
controlled hydrochlorothiazide (25 to 100 mg) was added in group I and
in group 2 additional antihypertensives were used if necessary (furose-
mide, prazosin, atenolol, and minoxidil). Group 1 pretreatment BP
175/104 mm Hg fell to 151/88 mm Hg with enalapril. Therapy was dis-
continued in one patient with uncontrolled hypertension and one who
developed transient impairment of renal function with renal artery ste-
nosis of a single functioning kidney. The remaining six patients have
DBP less than 95 mm Hg on 5 to 40 mg/day of enalapril hydrochlo-
rothiazide. In group 2 only one patient (renal transplant with previous
interstitial nephritis on captopril) achieved DBP less than 95 mm Hg
on enalapril alone (7.5 mg/day), three required additional therapy. In
two patients enalapril was ceased due to transient impairment of renal
function. One was subsequently shown to have bilateral renal artery
stenosis. The other had hypertensive nephrosclerosis with a normal re-
nal arteriogram and no interstitial nephritis on biopsy. She had previ-
ously developed impaired renal function on captopril. This suggests
that inhibition of angiotensin II formation can produce renal impair-
ment both in large (renal artery stenosis) and small vessel disease.
Efficacy of plasma exchange in experimental renal autoimmune dis-
ease. K. Schindhelm, A. J. Pollack, A. M. Wootton, A. J. Woodroffe,
B. Pussell, and P. C. Farrell. Centre for Biomedical Engineering, Uni-
versity of New South Wales, Renal Unit Prince Henry Hospital,
Sydney, and Renal Unit, Royal Adelaide Hospital, Adelaide, Aus-
tralia. Plasma exchange combined with immunosuppressive drug
therapy has given encouraging results in the treatment of Goodpasture
syndrome (GS). However, the individual roles of plasma exchange and
chemotherapy in altering the course of GS have not yet been estab-
lished. In this study plasmapheresis and immunosuppressive therapy
have been separately applied in a sheep model of autoimmune renal
disease. Twelve sheep (25 to 35 kg body weight) were induced with Steb-
lay nephritis via multiportal injections of 150 mg human gbomerular
basement membrane (GBM) in Freund's complete adjuvant given fort-
nightly until sacrifice. Renal function (51Cr-EDTA clearance), serum
biochemistries, whole blood and differential white cell counts, anti-hu-
man-GBM-antibody titers and urinalyses were used to monitor disease
progression. The sheep were divided into plasma exchange, chemo-
therapy and control groups. When renal function declined to about 50%
of the pre-disease function, treatment was initiated. The plasma ex-
change group had 1 liter of plasma exchanged with Haemaccel (Behr-
ing, Federal Republic of Germany) on six occasions over 8 days using
plasma filters (Enka AG., Federal Republic of Germany). The chemo-
therapy group received intravenous prednisobone (2 mg/kg) and
cycbophosphamide (4 mg/kg) daily until death. The control group was
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untreated. All data are reported as mean SEM (N = 4). Plasma ex-
change and chemotherapy significantly prolonged survival after dis-
ease onset (8.3 1.3 and 6.5 0.7 weeks, respectively, versus 2.8
0.6 weeks for controls). Preterminal renal clearances were 3.2 0.9
mi/mm for controls, 5.5 3.1 mI/mm for the plasma exchange group
and 38 5 mI/mm for the chemotherapy group. Plasma exchange re-
sulted in a transient reversal in the rate of decline in renal function,
while chemotherapy resulted in a sustained preservation or improve-
ment in renal function. Both control and plasma exchange animals died
in renal failure while the other group died as a result of chemotherapy
toxicity. Circulating anti-human-GBM-antibody levels were lowered by
chemotherapy, but plasma exchange did not cause a long-term de-
crease in the levels. This study indicates that both plasma exchange
and chemotherapy are effective therapeutic measures. Plasma ex-
change may preserve renal function by removing nonimmunoglobulin
inflammatory mediators, while the chemotherapy may reduce renal
deposition of immunoglohulin. Plasma exchange with concomitant
chemotherapy may be particularly effective by combining the removal
of mediators with a decrease in antibody production.
Plasmapheresis in nephrotoxic serum nephritis. J. E. Moran, C. G.
Roberts, K. Schindhelm, S. R. Holdsworth, and P. C. Farrell. Centre
for Biomedical Engineering, University of New South Wales, Renal
Unit, St. Vincent,s Hospital and Renal Unit, Prince's Hospital, Mel-
bourne, Australia. Nephrotoxic serum nephritis (NTN) is an accepted
model of antiglomerular basement membrane glomerulonephritis (anti-
GBM GN). NTN has been used as a disease model iii the evaluation
of treatment regimens such as defibrination, decomplementation, hep-
arm administration and immunosuppression. In this study, the effect of
plasmapheresis on the course of a telescoped model of NTN has been
investigated in a rabbit model. Eighteen NZ white rabbits (2 to 3 kg
body weight) were preimmunized with 4 mg normal sheep globulin in
Freund's complete adjuvant given i.m. Six days later 1.3 mI/kg nephro-
toxic serum (NTS) was given via an ear vein. The rabbits were then
randomly allocated into a control (N = 9) and treatment group (N =
9). On the day following NTS injection, blood access was created in
both treatment and control animals via an externalized carotid/jugular
shunt. Plasmapheresis was performed with membrane filters using a
plasma expander (Haemacel, Bchring, Federal Republic of Germany)
as the replacement fluid. One plasma volume was exchanged per treat-
ment. Plasmapheresis was given to the treatment group on days 2, 3,
5, and 7 following NTS injection. Serum biochemistries, and plasma 6-
brinogen, C3 and IgG levels were monitored daily in both groups. Se-
rum creatinine in the control rabbits rose following NTS injection to
peak at 0.65 0.12 mmoles/liter (mean SEM). Four control animals
died in renal failure (Cr > 0.8 mmoles/liter). Rabbits undergoing
plasmapheresis had peak serum creatinines of 0.29 0.04
mmoles/liter. Two treatment rabbits died from complications of
plasmapheresis and not renal failure (Cr < 0.29 mmoles/liter). Follow-
ing the treatment regimen (at day 9 post NTS injection) plasma fi-
brinogen was 3.5 0.2 ml/dl (mean SEM, N = 7) compared with
5.8 0.8 ml/dl (N = 7) for the control rabbits while plasma IgG lev-
els were 40% lower in the treatment group when compared with the
controls. Plasma C3 levels were only transiently lowered by plasma-
pheresis and at day 9, no difference was observed between the groups.
This study indicates that plasmapheresis preserves renal function dur-
ing the rapidly progressive phase of NTN. The preservation of renal
function may be associated with a decrease in levels of acute phase re-
actants associated with plasmapheresis as indicated by the lower lev-
els of circulating fibrinogen or by the removal of specific antibody di-
rected against sheep immunoglobulin.
Arteriolar C3 disease. M. A. B. Thomas and L. S. Ibels. Royal North
Shore Hospital, St. Leonards, New South Wales. There is contro-
versy over the existence of a distinct clinical syndrome of hematuria,
normal renal function, and deposition of complement in renal blood
vessels. The natural history of this syndrome has not been adequately
described. Of 546 renal biopsies performed over a 5-year period, 108
had complement deposition in extraglomerular vessels as the predomi-
nant finding. Of these 14 had a vasculitis, 8 had a chronic interstitial
nephritis, 4 had focal scierosing glomerulonephritis, and 17 had other
definitive renal diagnoses. In the remaining 65, there were 29 males,
36 females, aged 16 to 75 (mean 41) years of whom 46 had recurrent
hematuria (7 macroscopic), for 1 to 276 (mean 31) months, 22 had re-
current loin pain, for I to 480 (mean 67) months (3 requiring narcot-
ics), 21 had proteinuria for I to 48 (mean 13) months, 12 had hyper-
tension, for 5 to 288 (mean 80) months, 9 had edema, and 5 had had
synpharyngitic hematuria. Serum creatinine was 0.05 to 0.16 (mean
0.11) mmoles/liter, CCR 75 to 184 (mean 99) mI/mm. Urine protein loss
was less than 0.3 g/day in all but 2, 58 had abnormal urine sediments
with up to 480,000 RBC, 250,000 WBC, 150 hyalmne, 225 hyalogranu-
lar, or 2,500 granular casts per milliliter. Light microscopy showed no
abnormality in 37, mild mesangial increase in 15 and mild interstitial
scarring, or occasional glomerular sclerosis in 11. Immunofluores-
cence showed complement in afferent arterioles with granular mesan-
gial 1gM in 37, and light linear GBM IgG or granular mesangial IgA in
5. Follow-up for Ito 60 months has shown no decline in renal function
in any patient but persistent urine sediment abnormalities in all but
three patients. Loin pain persisted in 11. Hypertension developed in
one patient 6 months after diagnosis. Arteriolar C3 disease is a distinct
disease entity, a mild glomerulonephritis characterized by recurrent
loin pain and hematuria, and has a good prognosis.
'Malignant' focal glomerular sclerosis (FGS) in rats induced by com-
bined administration of puromycin-aminonucleoside (PAN) and prota-
mine sulfate (PS). T. Saito, E. Surnithran, E. F. Glasgow, and R. C.
Atkins. Department of Nephrology, Prince Henry's Hospital, Mel-
bourne, Australia. Persistent nephrotic syndrome and 'malignant' FGS
useful in analyzing mechanisms in the development of human FGS was
induced in rats by combined administration of PAN and PS, a polycat-
ionic protein. Six unilaterally nephrectomized 10- to 12-week-old male
Sprague-Dawley rats (group A) were injected daily for 4 days with both
PAN subcutaneously (1 mg/100 g BW) and PS intravenously (5 mg/l00
g BW/day). This protocol was repeated at 10-day intervals on three oc-
casions (Pan now 0.5 mg). The animals were sacrificed 80 days after
the initial injection. Another three groups were given a similar series
of injections of PAN and saline (group B), PS alone (group C), and sa-
line (group D). Urinary protein, serum albumin, urea, creatirline, and
cholesterol levels and creatinine clearances were measured in each ani-
mal fortnightly. In group A there was marked proteinuria in all ani-
mals and hypoalbuminemia and hypercholesterolemia were observed.
Serum urea and creatinine levels gradually increased until sacrifice.
Histologically most glomeruli in this group showed varying degrees of
segmental sclerosis without cellular proliferation. There was a marked
increase in interstitial mononuclear infiltration. Ultrastructurally there
was expansion of mesangial matrix and extension into capillary loops
without proliferation, and some reduplication of capillary walls with
interposition of cytoplasm. In group B rats there was less marked pro-
teinuria with slight hypoalbummnemia and hypercholesterolemia but
these remained normal in groups C and D. The group A rats demon-
strated marked nephrosis and morphological lesions identical to se-
vere human FGS, unlike previous experimental PAN nephrosis which
has been accompanied by only mild glomerular changes. The combi-
nation of PAN with PS produces a 'malignant' lesion more akin to hu-
man FGS and therefore more useful for investigating mechanisms in-
volved in the development of human FGS.
Development of an extracorporeal immunoadsorption system utilizing
monoclonal antibodies. D. H. Randerson, K. Y. Pak, and Z. Steplew-
ski. Department qf Chemical Engineering, University of Queensland,
Brisbane, Australia, and Extracorporeal Inc., King of Prussia, and
Wistar Institute, Philadelphia, Pennsylvania. An immunoadsorption
system of monoclonal antibody immobilized within the pores of a mi-
croporous polyolefin membrane has been developed for the on-line ex-
traction of circulating substances from plasma and whole blood. The
membrane support was in capillary form with an inner diameter of 300
jsm, wall thickness 140 zm, and with a maximum pore size of 0.6 to
3.0 zm. The membrane was capable of binding approximately 0.1 mg
antibody/cm2 luminal surface area via hydrophobic interaction. The
system was evaluated in vitro for the extraction of circulating gastro-
intestinal cancer antigen (GICA). The monoclonal antibody
11 16—NS—19—9 specific for human GICA was purified from ascites fol-
lowing murine culture of the hydridoma. Continuous circulation of 50
ml of high GICA titer plasma from colorectal cancer patients through
the antibody-membrane matrix resulted in 90% depletion of GICA in 2
hr using 0.6 mg immobilized antibody, and 90% depletion in 5 mm
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using 8 mg antibody. Desorption of antibody into diseased serum was
less than 0.5% of total bound per hour. The results indicate that a 300
cm2 device containing 30 mg of monoclonal antibody, perfused at 30
mi/mm by plasma would efficiently deplete the majority of circulating
antigen from a patient with high GICA levels. This methodology pro-
vides a selective and convenient means for removing any monoclonal
antibody targeted substance from the circulation, and thus overcomes
many of the shortcomings associated with conventional plasmapher-
esis. The system could find applicability in the treatment of Goodpas-
ture syndrome, renal allograft rejection, and systemic lupus erythema-
tosus.
The use of silver methenamine impregnation for renal electron micros-
copy. J. P. Dowling, D. C. Mathews, and P. Kincaid-Smiih. Depart-
ments of Anatomical Pathology and Nephrology, Royal Melbourne
Hospital, Parkville, Victoria, Australia. A wide variety of pathological
changes of the glomerular basement membrane (GBM) form an inte-
gral part of the morphological classification of glomerular disease.
These alterations can be frequently outlined by the application of con-
ventional silver methenamine impregnation of thin sections (1 to 2 )
of renal biopsy specimens for light microscopy and by Uranyl-lead
staining for transmission electron microscopy. In some cases the
subtlety or complexity of the GBM lesions can be more clearly dem-
onstrated by silver methenamine impregnation applied to Epoxy resin-
embedded tissue. We have studied renal biopsy specimens ultrastruc-
turally using Epon-embedded sections cut at 500 to 700 A with an ul-
tra-microtome and stained with SM for approximately 10 mm at 75°C
in a humid atmosphere. Within this technique such changes as the early
spike formation of membranous nephropathy, the irregularities of the
GBM related to minimal change glomerulopathy and focal glomerulo-
sclerosis, the "fraying" of the GBM in early Alport syndrome are dem-
onstrated more clearly by this staining method. It is especially useful
in distinguishing between the different subvarieties of mesangiocapil-
lary glomerulonephritis where the relation between deposited material
and GBM alterations defines the morphological entities. The method
had been useful in outlining the ultrastructural lesions in glomeru-
lopnephritides difficult to subclassify. Examples of these various con-
ditions will be illustrated.
Aminophylline reduces the severity of glycerol.induced acute renal fail-
ure in the rat. R. Nordon, G. Macdonald, and J. Charlesworth. The
Prince Henry Hospital, Sydney, New South Wales. We have estab-
lished that uridine causes vasoconstriction in the isolated perfused rat
kidney and that minoxidil blocks the pressor effects of uridine in the
intact rat. Osswald and co-workers have shown that adenosine also has
vasoconstrictor effects in the rat kidney which are competitively an-
tagonized by theophylline. Theophylline also limits the fall in renal
blood flow which results from 30 sec of renal artery occlusion. Os-
swald and co-workers described a threefold increase in plasma adeno-
sine following release of total renal artery occlusion and hypothesized
that adenosine release from ischemic tissue might cause the accompa-
nying reduction in renal plasma flow. To test the role of nucleoside
vasoconstrictors in glycerol-induced acute renal failure in the rat, theo-
phylline or minoxidil was infused for the first 8 hr following the in-
jection of 10 ml/kg 50% glycerol into the glutei, with saline or mi-
noxidil vehicle infused into paired controls. Blood pressure and blood
samples for plasma creatinine and urea were taken from aortic cath-
eters and urine collected from the rats in metabolic cages. Aminophyl-
line significantly reduced the rate of increase of azotemia. At 24 hr the
aminophylline and saline control groups had plasma creatinine of 0.173
0.038 mM(sE), N = 6 and 0.276 0.033 mvt, N = 7 (P < 0.05).
Urine flow was significantly increased during aminophylline infusion
compared to controls (mean 1.582 0.252 ml/hr, controls 0.377
0.150 ml/hr). Although minoxidil infusion significantly lowered mean
blood pressure by 20 to 30 mm Hg for 24 hr, it had no protective effect
against acute renal failure. Both minoxidil and aminophylline pre-
vented the drop in heart rate seen during the first 8 hr of the model.
The mechanism of aminophylline's protective effect cannot be de-
duced from this experiment. It seems likely that aminophylline may he
opposing the vasoconstrictor action of adenosine.
Binding studies with isolated glomerular basement membrane (GBM).
A. M. Wooton and A. J. Woodroffe. Clinical Chemistry, Institute of
Medical and Veterinary Science and Renal Unit, Royal Adelaide Hos-
pital, Adelaide, Australia. The binding of various compounds to iso-
lated human GBM was investigated since this may have a role in the
etiology of immune deposit renal disease. Lyophilized GBM was soni-
cated and incubated overnight at 4°C with the compounds listed be-
low. Specifically bound radioactivity was calculated by comparison
with tubes containing no GBM. The following results were obtained:
Normal IgG (—ye) cationized IgG (+ve)
Neuraminidase treated IgG (_ve)* 311-DNA (+ve)
14C-Captopril (—ye) 195Au (—ye)
203Hg (+ve) '251-Clq (+ve)
* Tested by indirect immunofluorescence.
The binding curves for normal and cationized IgG are shown below.
Saturation of the GBM binding sites with cationized IgG occurred at
about 8 ng/pg dry wt.
0 NormallgG
100 1000
ng IgG added
The data obtained using normal IgG (— ye control) and DNA (-f- ye
control) suggests that this is a suitable system for testing in vitro bind-
ing to GBM.
Renal transplantation in patients on CAPD. C. Wood, N. M.
Thomson, D. F. Scott, S. R. Holdsworth, V. Marshall, and R. C. At-
kins. Department of Nephrology, Prince Henry's Hospital, Mel-
bourne, Australia. Concern has been expressed that renal transplan-
tation in patients on CAPD is associated with poor graft survival and
problems with peritonitis in the early post-transplant period. In the last
5 years we have performed 33 renal transplants (29 cadaveric, 4 living
related) in 32 patients on CAPD. Cadaveric graft survival and patient
survival have been compared to that of 96 hemodialysis (HD) patients
transplanted in the same period. Complications of leaving the intraperi-
toneal catheter in situ post-transplantation were also assessed. The
mean ages of CAPD and HD patients were 37.2 years and 39.3 years,
respectively. Eighty percent of CAPD patients and 82% of HD pa-
tients had received one or more blood transfusions prior to transplan-
tation. Cadaveric graft survival at 1 year was 49 and 51% for CAPD
and HD patients, respectively (P > 0.1), but improved to 59 and 56%,
respectively, when only transfused patients were considered. Graft
survival was 23 and 31% for non-transfused CAPD and HD patients,
respectively. Patient survival at 1 year was 96 and 86% for CAPD and
HD patients, respectively; only 1 CAPD patient died (CMV colitis).
The Tenckhoff catheter was removed perioperatively in six patients
and left in situ in 27. The catheter was subsequently removed 11/2 to
10 weeks later in 20 patients. CAPD was continued in the postopera-
tive period in 13 patients. Only seven episodes (in five patients) of peri-
tonitis occurred postoperatively, all episodes responding rapidly to
antibiotics. Six of these episodes occurred in patients dialyzed post-
operatively. This study shows that graft and patient survival in pa-
tients transplanted while on CAPD is equal to that for patients on HD.
Moreover, although the numbers are small, pretransplant blood trans-
fusions seem to be as important in improving graft survival in CAPD
patients as they are in HD patients. The study has also shown that the
peritoneal catheter may be safely left in situ during the postoperative
period and used if necessary for dialysis.
Fungal peritonitis on CAPD. N. W. Boyce, S. R. Holdsworth, N. W.
Thomson, and R. C. Atkins. Departments of Medicine and Nephrol-
ogy, Prince Henry's Hospital, Melbourne, Australia. We review fun-
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gal peritonitis (FP) complicating CAPD at our unit. Sixteen episodes
occurred in 14 patients. FP accounted for 1.8% of microbiologically
proven peritonitis episodes. Pathogens involved were: Candido a/hi-
cans (9); Candida tropical/s (4); Rhodotonn'o (2), and Cant/ida gui//i-
ers'nondi (1). l'he clinical presentations of FP and bacterial peritonitis
did not differ. Peritoneal differential WCC's showed a polymorphonu-
clear leucocytosis as in bacterial peritonitis. Fungi were recognized on
initial gram stain of peritoneal effluent in seven of 16 episodes (44%),
All fungi grew on routine culture media within 3 days. FP was often
associated with multi-organism peritonitis (12 of 16). Twelve patients
with FP had experienced recurrent episodes of bacterial peritonitis
(mean, 6.3 prior infections) with exposure to multiple antibiotics. We
believe this to be the major predisposition to developing PP. Various
therapeutic regimens were used (combinations of catheter removal, an-
tifungal intraperitoneal lavage with amphotericin and 5FC and sys-
temic antifungal therapy with amphotericin, 5FC and micronazole).
Four deaths occurred (mortality 28.6%). Three of four deaths were as-
sociated with delayed catheter removal. Three attempts to re-
commence CAPD were unsuccessful because of peritoneal membrane
failure. We recommend (1) early detection of high risk patients with
transfer to alternative dialysis techniques; (2) treatment with initial
combined antifungal lavage and systemic antifungal chemotherapy fol-
lowed by early catheter removal.
Fungal peritonitis in CAPD patients. J. Moran, C. Wright, D. Si/k,
A. Heazlewood, J. Andrew, and 2. Nm/I. St. Vincent's Hospital, Mel-
bourne, Australia. Among 69 patients trained for CAPD over 5.5 years,
12 episodes of fungal peritonitis have occurred in 11 patients. Only one
case arose de novo. Most cases (eight) occurred following antibiotic
therapy for bacterial peritonitis (seven cases) or UTI (one case). One
case was due to a perforated sigmoid diverticulum and the one recur-
rent case followed spontaneous vaginal leak of dialysate. Nine of 11 pa-
tients (82%) were female (compare with 45% of total CAPD popula-
tion). The clinical features were indistinguishable from those of bac-
terial peritonitis, save that most patients presented as a "relapse" of
an apparently resolved or resolving episode of bacterial peritonitis. In
seven of the II patients, gram stain of the dialysate was positive and
culture revealed Candida species in ten patients (8 C. albicans, 1 C.
parapsilosis, 1 C. tropicalis) and an unidentified yeast in the patient
with recurrence. No patient responded to antifungal therapy and all re-
quired removal of the Tenckhoff catheter before resolution occurred.
Morbidity was severe (hospital stay 13 to 190 days; mean, 50 days) and
one patient died, No patient was able to resume CAPD. In this group
fungal peritonitis was the most important cause of treatment failure (II
of 69 patients) (16%). Attempts to conserve the Tenckhoff catheter are
futile and lead to increased mobidity. Removal of the catheter on di-
agnosis is mandatory and the only effective therapy.
Estimation of blood biochemistries from dialysate levels following over-
nigbt dwell. P. C. Spencer, S. M. Forbes, and P. C. Farre//. The Cen-
tre for Biomedical Engineering, The University of' New South Wa/es,
Kensington, New South Wa/es. The advantages of a technique allow-
ing estimation of small solute plasma biochemistries from overnight
dwell dialysate are clear. These include: increased convenience es-
pecially for country patients who could send samples in for analysis;
decreased blood loss where very frequent (daily) analyses are required
to follow dialysis adequacy, or the levels of particular solutes. Al-
though the need for information on larger molecular weight solutes
such as proteins would still require blood sampling, potential equili-
bration between low molecular weight, metabolites and electrolytes
during overnight dwell, would reduce the overall requirement for ye-
nipuncture. Thirty patients are being assessed (10 x 4,20 x I) by tak-
ing simultaneous blood and dialysate samples from overnight dwell di-
alysates; complete biochemical analyses are being done. Results to
date for 7 x 4 patients, expressed as mean dialysate/plasma ratio
(C0/C mean sD) are as follows: sodium 0.98 0.02; potassium 0.90
0.07; chloride 1.09 0.02; bicarbonate 1.00 0.06; urea 1.01
0.03; creatinine 0.93 0.08; calcium 0.59 0.05; inorganic phos-
phate 0.94 0.1. The results for calcium are explained by the exis-
tence of 40% serum protein binding levels leaving 60% calcium free for
equilibration with dialysate. The C0/Cp ratio for calcium also linearly
correlated with both total serum protein and albumin levels. The re-
sults also demonstrate the classic Donnan membrane equilibria for
electrolytes, particularly in the case of chloride ions where protein ex-
clusion and Donnan effects work in the same direction. Two-way
analysis of variance for each solute showed that significant C0/C dif-
ferences existed between patients for Nat, HCO3, urea, Ca2 and 1
(P < 0.05). For these solutes, accuracy of estimates would improve if
ratios were calculated initially for each patient under study, rather than
using the mixed patient ratios given. The results suggest that over-
night dialysate may be used to obtain accurate serum level estimates
of the salutes tested.
Peritoneal membrane after five years of CAPD. P. C. Spencer, D. H.
Randerson, R. J. Righy, and P. C. Farrell. 1/ic Centre .for Biomedical
Engineering, The University of New South Wales, Kensington, New
South Wales. '[he ability of the peritoneal membrane to allow ad-
equate dialysis fur CAPD patients over lang periods (> 5 years) is as
yet unknown. In conjunction with the Renal Unit at Princess Alexan-
dra Hospital, Brisbane, Australia. we studied one of their first CAPD
patients when she commenced CAPD in October 1978 and during 1979(N = 3). During this period her weight was 52 2 kg (mean so)
and she was doing 9 >< I liter exchanges daily. The study involved es-
timating maximum clearance rates or mass transfer coefficients (Kuu's)
for urea, creatinine, and vitamin B12 as well as measuring the patient's
protein catabolic rate (PCR) and daily dialysate protein loss. At the end
of September 1983 all tests were repeated, except for the Kau measure-
ment for vitamin B12. At this time the patient was doing 7 x I liter
exchanges daily and her weight at 50 kg had nat significantly changed
aver the 5-year period. Since beginning CAPD the patient had expe-
rienced three bouts of peritonitis, all during 1980 (one episode every
20 months). The maximum clearance estimates (K50's) far urea and
creatinine were not significantly different after 5 years of dialysis, as
shown in the accompanying table:
Variatians in Kuu (mI/mm) with time (weeks)
Time 5 25 36 252
Solute
Urea 17 31 29 32
Creatinine 12 19 14 20
Negligible variation in peritnneal membrane permeability appears to
have occurred over this period. The dietary protein intake, estimated
from the PCR and the dialysate protein loss, showed the patient to be
eating about 30% more protein daily at 77 g/day versus the 1978 to 1979
level of 59 6 g/day (mean so). Of this..30% increase, approxi-
mately 7% could be accounted for by increased dialysate losses; daily
protein losses had risen from 14 2 g/day (mean SD) O 1978 to 1979
to 18 g/day in 1983. These data are based on the long-term CAPD expe-
rience of only one patient and should therefore be treated with appro-
priate circumspection.
Relationship of plasma glucose perturbations during hemodialysis to
dialysate buffer anion. F. So rd/c, M. Parmentier, and D. McDermott.
Department of Renal Medicine, Royal North Shore Hospital, St. Leon-
ords, New South Wales. Recent work suggests that acetate (A) and bi-
carbonate (B), when used as buffer anions in hemodialysis, might have
different effects on plasma electrolytes and intermediary metabolism.
To study this question, we carried out a randomized cross-over study
of biochemical perturbations in ten (2M, 8F) stable maintenance dial-
ysis patients during fasting hemodialysis against either A (40
mmoles/liter) or B (35 mmoles/liter)-eontaining glucose-free dialysates.
Blood taken pre-dialysis and 1, 2. 3, and 4 hr after commencement and
again one-half hour post-dialysis (dialysis length 4.5 hr) showed no sig-
nificant differences in plasma K +, P04, or other electrolyte levels be-
tween A and B dialysis. Pre-dialysis plasma glucose concentrations
were similar before A and B dialysis [7.77 0.48 (so) and 7.67 0.45
mmoles/liter, respectively]. Both modes of dialysis caused a clear de-
crease in these eonceotrations. However, whereas glucose levels fell
gradually over 4 hr with B dialysis, to 4.62 0.22 mmoles/liter (P c
0.001), the reduction with A was much mare rapid; at 1 hr mean glu-
cose levels were 4.94 0.39 with A compared with 7.26 0.40
mmoles/liter with B (P < 0.001). Plasma insulin levels behaved appra-
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priately to the glucose concentrations, with a rapid reduction in A dial-
ysis, and a gradual decrease with B. These results suggest that glu-
cose-free baths containing acetate as buffer anion have a steep hypo-
glycemic effect. This is not due to acetate acting as an insulin secre-
tagogue but may be due to demands on oxaloacetate for acetate
metabolism, thus limiting gluconeogenesis in response to diffusive glu-
cose loss to the bath.
Tenckhoff catheter placement in the superior vena cava as hemoaccess
for dialysis. M. M. Rao, M. Y. Mudaliar, and A. P. S. Disney. Renal
Unit, The Queen Elizabeth Hospital, Adelaide, Australia. Subclavian
vein catheterization which has gained increasing popularity for he-
moaccess since 1979. may require frequent canula and catheter re-
placement and is prone to develop infective and thrombotic complica-
tions. Under local anesthesia, a standard double-cuffed Tenckhoffcath-
eter was surgically introduced into the external jugular vein and ma-
nipulated gently until its tip was at the junction of the superior vena
cava and right atrium. The catheter was brought out through a curved
subcutaneous tunnel to exit about 3 cm below the mid-clavicular line.
Hemodialysis was performed using a single needle technique, blood
flow rates 150 to 230 mI/mm. with a recirculation of 9 to 15% (com-
pared to 9 to 12% with Vascath) and venous pressure fall 250 to 75 mm
Hg in 5 sec. Catheter patency was maintained by flushing with 1000 U
heparin in 4 ml normal saline four times a day. Four patients have been
treated for a total period of 26 weeks (longest 10 weeks) and a com-
bined total of 80 dialyses. No catheter thrombosis or infection or re-
placement has been necessary. The advantages of this technique are:
(I) easily maintained catheter patency; (2j higher blood flow rate, com-
pared to single lumen Vascath; (3) more efficient dialysis from in-
creased cycles per minute; and (4) frequent catheter changes are not
necessary making it more acceptable to patients.
Factors influencing drinking behavior in patients on chronic dialysis.
T. Birbara, B. Oldenburg, R. Perkins, and G. Macdonald. The Prince
Henry Hospital, Sydney, New South Wales. To study excessive inter-
dialytic weight gain, 12 women and 14 men on hospital hemodialysis
completed questionnaires relating to psychosocial factors and drinking
behavior. Blood was taken pre-dialysis to measure concentrations of
solutes with possible significance in dipsogenesis. Interdialytic weight
gain was significantly related to water intake (r = 0.43) and drinking
occasions (r = 0.48). Mean interdialytic weight gain, fluid intake, and
frequency of drinking were negatively correlated with plasma Na (r
=
—0.77, 0.76, and 0.59. respectively) consistent with hemodilution
between dialyses. There were no significant relationships between
plasma concentrations of active renin or angiotensin II and indices of
water intake. Although instances of strong desire for food were little
changed from the premorbid state (r = 0.78), patients reported marked
changes in their attitudes to drinking and its importance at home and
in their social lives. There appeared to be an acceptance of water re-
striction and reordering of routines to facilitate adherence to regimes.
There were some interesting correlations between biochemical and
psychological results. A craving for food correlated strongly with
plasma angiotensin II (r = 0.64) and active renin concentration (r =
0.68) and locus of personal control correlated with plasnia angiotensin
II (r = 0.69). We concluded that social and psychological factors and
medical and nursing information were the dominant influences on wa-
ter intake in these patients. We were unable to establish any link be-
tween biochemical and humoral indices and water intake.
Hemofiltration versus hemodialysis in chronic renal failure. K. F. fur-
eidini, P. Pepper, G. Sturinan, and R. J. Hogg. IVephrology Unit, Ad-
elaide Children's Hospital, North Adelaide, South Australia. He-
mofiltration has been used in two children with chronic renal failure.
The first patient, a 17-year-old, 36 kg male, was transferred to he-
mofiltration after poor tolerance of hemodialysis. A (Jambro he-
mofiltration machine with a single head blood pump was used with 16-
liter fluid exchange with a Gambro FH-202 hemofilter. Tolerance of
treatment was significantly improved with fewer hypotensive epi-
sodes, and generally improved well-being between treatments. Hemo-
globin levels remained normal for far longer periods with hemofiltra-
tion and, while clearance of creatinine and urea was slightly lower,
control of acidosis was improved. A further short period on hemodi-
alysis confirmed improved patient tolerance with hemofiltration. The
second patient placed on hemofiltration was a 56-kg, 12-year-old girl.
Poor fistula access and patient compliance indicated the need for sin-
gle needle technique. A Gambro BMM 10-4 double head single needle
blood pump was used with the hemofiltration unit with a FH-202 he-
mofilter, and 16-liter fluid exchanges. Mean treatment time was 3.7 hr,
with an ultrafiltration rate of 80 mI/mm. Urea and creatinine clearance
has been good, as has patient tolerance of large volumes of fluid
removal.
